



The Norwegian College of Fishery Science, UiT The Arctic University of Norway 
Exploring the Potential of Two Arctic Marine Bacteria 
for the Production of Bioactive Metabolites 
 
Marte Jenssen 







This master thesis was conducted at Marbio, Norwegian College of Fisheries. The project lasted 
from August 2016 until June 2017, and concluded my master’s degree in Marine Biotechnology 
at UiT The Arctic University of Norway.  
I would like to thank all my supervisors: Jeanette Hammer Andersen, Espen Hansen, Venke 
Kristoffersen and Kine Østnes Hansen. I could not have asked for a better team of supervisors. 
I would also like to thank everyone else at Marbio, Marbank and the Arctic Biodiscovery Centre 
for creating a great work place atmosphere. I always had someone to share my frustrations and 
joys with. A special thanks to Marte Albrigtsen for your help with the bioactivity screening.  
To those of you who have made my life outside of the university easier: My family, my friends 
and my significant other. Thank you for all your love and support. Thanks to all my fellow 
students for five great years. A special thanks to Therese for an amazing exchange semester in 
Uppsala, and to Eirin and Hanne for being the best office mates.  
 






The number of compounds being isolated from the marine environment is increasing, and there 
is a great potential for discovering new marine derived drug candidates. Improved collection 
techniques has strengthened bioprospecting on a wider diversity of marine microorganisms. 
The focus on microorganisms has led to the realisation that many of the natural products 
originally isolated from macroorganisms, are metabolic products produced by their associated 
microorganisms. This, and the fact that most marketed antimicrobial drugs originate from 
microorganisms, motivated the work conducted as part of this thesis. 
In this study, two Arctic marine bacteria of the genus Leifsonia and Polaribacter were studied. 
The “One Strain-Many Compounds” (OSMAC) approach was utilised when cultivating the 
bacteria, in an attempt to trigger the bacteria into activating different metabolic pathways and 
producing compounds with interesting chemistry and bioactivity. Seven different cultivation 
treatments were used, varying different parameters e.g. media composition and temperature. 
The secondary metabolites secreted by the cultivated bacteria were harvested, extracted and 
prefractionated. The fractions were screened for antibacterial activity, inhibition of biofilm 
formation and anticancer activity. The bioactivity screening resulted in eight active fractions. 
Dereplication of the active fractions gave several candidates that could be responsible for the 
observed bioactivity. The results from this thesis give a valuable starting point for further 
research on cultivation of Arctic marine bacteria, with the purpose of producing bioactive 
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1.1 Natural products 
Natural products (NPs) are substances produced by a living organism. One common way of 
subdividing the NPs is into primary and secondary metabolites. Primary metabolites are 
compounds that are necessary for the immediate survival and growth of the organism. 
Secondary metabolites, on the other hand, are not necessary for the survival, growth or 
reproduction of the organism, but can offer advantageous properties by acting as e.g. defence 
molecules. The compounds are often unique for a set of species within a phylogenetic group 
(Sarker & Nahar, 2012b). In this thesis, the focus will be on the secondary metabolites produced 
and secreted into the culture medium by cultivated Arctic marine bacteria.  
NPs have evolved to interact efficiently with their biological targets. Because of this, NPs have 
proven to be good starting points for drug discovery (Montaser & Luesch, 2011). NPs have 
been the most prolific source of active ingredients for drugs, and have given rise to drugs within 
many different classes, e.g. anti-cancer, anti-infective and anti-diabetic. An advantage with NPs 
is that they are, on average, better absorbed (has higher oral availability) compared to synthetic 
drugs (Harvey, 2008). NPs are often architecturally more complex, contain more ring structures 
and have higher molecular weight than synthetic compounds (Henkel, Brunne, Müller, & 
Reichel, 1999). These structural features make NPs capable of interacting with biological 
targets with high specificity and potency (Hansen & Andersen, 2016). Figure 1 gives an 
overview of all approved drugs from 1981-2014, as well as the origin of the drug, illustrating 
that many of the drugs either are NPs or have some connection to NPs, through a NP 
pharmacophore or by being mimics of NPs. The purely synthetic drugs (S) have only 




Figure 1: Sources of new approved drugs from 1981-2014 (n=1562). B = Biological macromolecule, N = 
Unaltered natural product, NB = Botanical drug (defined mixture), ND = Natural product derivative, S = 
Synthetic drug, S/NM = Synthetic drug/mimic of natural product, S* = Synthetic drug (NP pharmocophore), 
S*/NM = Synthetic drug (NP pharmocophore)/mimic of natural product, V = Vaccine. Modified from reference 
(Newman & Cragg, 2016, p. 631). 
1.2 The marine environment 
More than 70% of the Earth’s surface is covered by the oceans. The marine environment is a 
diverse and ever changing habitat, ranging from the deep-sea trenches with low temperatures 
and high pressure, to the epipelagic zone with access to sunlight (National Weather Service, 
n.d.). Marine organisms have generated the ability to adapt to this hostile environment by 
producing specialized chemical compounds (Svenson, 2013). Compared to the terrestrial 
environment, the marine environment has many unique characteristics: High salinity, high 
hydrostatic pressure and low concentrations of organic matter. Because of this, organisms in 
the marine environment are metabolically and physiologically different from organisms 
inhabiting other habitats (Imada, 2013).  
1.2.1 Marine bioprospecting 
Bioprospecting is the search for biologically active substances from nature, with the potential 
of being developed into a product that should be commercially and scientifically profitable, and 
valuable to the community (Capon, 2001). The Norwegian Government is focusing on marine 
research, and in a national strategy from 2009 they defined marine bioprospecting as: “Targeted 
and systematic search for components, bioactive compounds or genes within marine 
organisms” (Regjeringen, 2009, p. 13). The goal of marine bioprospecting is to discover 
compounds that are applicable as products or in processes, and that can be relevant for different 
fields and industries, e.g. human medicine, animal feed, oil and gas (Regjeringen, 2009). This 
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thesis will focus on the use of marine natural products (MNPs) as lead compounds with the 
potential of being further developed into commercially available pharmaceutical products.  
1.3 Marine natural products 
For a long time, NPs have been a traditional source of drug molecules, especially those from 
terrestrial plants and microbes. The interest in the marine environment was put on hold until 
better collection technologies, such as scuba diving, emerged (Gerwick & Moore, 2012; 
Molinski, Dalisay, Lievens, & Saludes, 2009). In the later part of the twentieth century, the 
interest in marine biodiversity for exploration, extraction and commercialisation has grown 
(Demunshi & Chugh, 2010). Much less is known about marine organisms than terrestrial ones, 
and the marine environment is considered largely unexplored with regards to NP discovery 
(Sarker & Nahar, 2012b). Nevertheless, the marine environment with its rich biodiversity has 
afforded researchers with a wealth of novel bioactive compounds, some of which have been 
developed into drugs (Molinski et al., 2009). There are several success stories: One of the most 
known examples of drugs from the sea is the peptide ziconotide, marketed under the trade name 
Prialt®. Prialt® was approved in 2004 in the United States for treatment of chronic pain. The 
peptide was isolated from the tropical marine cone snail Conus magus, who uses the peptide to 
paralyse its preys (Bowersox & Luther, 1998; Molinski et al., 2009). Another known drug with 
marine origin is the antitumor compound trabectedin, marketed as Yondelis®, which was 
isolated from the tropical sea squirt Ecteinascidia trubinata. The drug was approved in 2007 
by the European Commission for treatment of soft tissue sarcoma (Aune, Furuta, & Pommier, 
2002; Molinski et al., 2009). Each year, more and more MNPs are reported, increasing from 
332 in 1984 to 1378 in 2014 (Blunt, Copp, Keyzers, Munro, & Prinsep, 2016). Figure 2 shows 
the steep increase in the discovery of new MNPs, which has accelerated greatly, especially in 




Figure 2: The number of new compounds isolated from marine organisms per decade from 1970 to 2010. Modified 
from reference (Mehbub et al., 2014, p. 4541). 
Many of the compounds from the ocean have no terrestrial analogues and have unique structures 
and biological activities. This makes them especially interesting in the search for new human 
medicines (Jaspars et al., 2016). Uncommon functional groups, arising from e.g. halogenation, 
are often incorporated in the MNPs, which is a special trait for these molecules (Rocha-Martin, 
Harrington, Dobson, & O'Gara, 2014; Villa & Gerwick, 2010). Another important aspect with 
regards to the potency of MNPs is the fact that they are diluted by the surrounding water, and 
because of this evolution has favoured the production of particularly potent MNPs, in order for 
them to exert the desired effect on their target (Newman, Cragg, & Battershill, 2009).  
1.3.1 Marine natural products from microorganisms 
The interest in bioprospecting of smaller organisms like marine bacteria and fungi for MNP 
drug discovery has increased. This has provided new chemistry, but also the realization that 
many compounds previously isolated from macroorganisms actually were metabolic products 
from their associated microbes (Gerwick & Moore, 2012; Piel, 2009). In a review by Gerwick 
and Moore, it was predicted that associated microorganisms were the actual producers of about 
80% of the approved agents and agents in clinical studies (as of 2012) (figure 3). Several of the 
approved marine derived drugs from macroorganisms were predicted to be produced by 





Figure 3: The collected sources (A) and predicted biosynthetic sources (B) of marine derived or inspired drugs 
and clinical trial agents. Based on a total of 20 agents that are either approved drugs or in clinical trials as of 
2012. Modified from reference (Gerwick & Moore, 2012, p. 90). 
There has been a great increase in the number of new metabolites reported from marine 
microorganisms (677 in 2016 vs. 493 in 2013), but the number reported for marine bacteria has 
not increased much (164 in 2016 vs. 158 in 2013) (Blunt et al., 2016). One advantage with 
bioprospecting on microorganisms is that cultivation can aid in overcoming the supply issue 
that is often associated with NP drug discovery from macroorganisms. Cultivation makes it 
possible to produce large amounts of the source of the NP, and therefore sufficient amounts of 
the NP for isolation and further testing and development (Gulder & Moore, 2009; Hansen & 
Andersen, 2016). There are examples of success stories from MNP drug discovery from 
microorganisms as well, one of the most known being the proteasome inhibitor 
Salinosporamide A, isolated from the marine bacterium Salinispora tropica. Salinosporamide 
A, also known as Marizomb, is in phase 1 human clinical trials for the treatment of multiple 
myeloma (Gerwick & Moore, 2012; Potts et al., 2011). The potential of marine microorganisms 
as producers of bioactive NPs appears to be massive. 
1.4 Bacteria 
1.4.1 The microbial growth cycle 
Bacteria growing in an enclosed vessel, like in a batch culture, can not grow exponentially 
forever. Eventually a negative feedback between growth rate and one or several parameters in 
the vessel will lead to a steady number of cells, and will ultimately result in a reduction in cell 
number. These parameters include nutrient availability, accumulation of waste products, pH 
changes, cell density, and dissolved oxygen concentration. The microbial growth cycle begins 
with a lag phase: A period straight after inoculation, before growth has started. In this phase, 
the bacteria synthesise the enzymes that are needed for growth in the particular medium. 
6 
 
Following the lag phase comes the exponential phase, where the bacteria are dependent on 
available resources to sustain exponential growth. The rate of exponential growth can vary a 
lot, and is highly influenced by environmental factors like temperature and availability of 
nutrients. In the stationary phase, the above listed limitations to growth expansion has been 
reached, causing the bacterial number to enter a steady state where there is not an increase nor 
a decrease in cell number (Madigan, Martinko, Stahl, & Clark, 2012, p. 151-156). Figure 4A 
demonstrates the different phases of the microbial growth cycle. Temperature and other 
environmental factors have considerable influence on the growth rate of bacteria, both in their 
natural habitat and in batch cultures. The temperatures where different bacteria grow can vary 
greatly and are normally reflected by the conditions in the natural habitat of the organism. 
Bacteria are often classified based on the temperature range in which they are able to grow 
(figure 4B). Psychrophiles have low temperature optima, mesophiles have midrange 
temperature optima, while thermophiles and hyperthermophiles have a high temperature optima 
(Madigan et al., 2012, p. 160-166).  
 
Figure 4: A) The different phases of the microbial growth cycle. Modified from reference (Madigan et al., 2012, 
p. 153). B) Classification of microorganisms, based on the ranges of temperature in which they are able to grow. 
Modified from reference (Madigan et al., 2012, p. 163). 
1.4.2 Marine bacteria 
The average temperature of the oceans is 5°C, and at the depths the temperatures are normally 
constant around 1-3°C. The microorganisms that grow in the marine environment are generally 
psychrophiles with temperature optima of 15°C or lower. Psychrophiles produce enzymes that 
function optimally at low temperatures, and are inactivated at moderate temperatures. Seawater 
contains dissolved halogen atoms, with about 3% sodium chloride. Many of the marine bacteria 
are therefore also halophiles, meaning that they require sodium chloride to grow optimally 
(Madigan et al., 2012, p. 169-171). One of the main limitations of bioprospecting on marine 
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microorganisms is the lack of knowledge regarding their nutritional needs and environmental 
requirements. Using standard laboratory techniques, only a small proportion of the microbial 
diversity of the marine environment is captured (Joint, Mühling, & Querellou, 2010). The vast 
majority of marine bacteria still remain to be cultured under laboratory conditions, and it is 
estimated that only 1% of the bacteria present in the sea has been cultured (as of 2012), and that 
many major lineages still have not been successfully brought to culture (Gerwick & Moore, 
2012). The problem is two-sided: In order to acquire more knowledge about cultivation of these 
organisms, they have to be grown in laboratory cultures, but to grow the organisms in laboratory 
cultures, more knowledge is needed about their cultivational needs (Joint et al., 2010). In this 
thesis, two Arctic marine bacteria, one from the genus Leifsonia and one from the genus 
Polaribacter, were cultivated.  
1.4.2.1 The genus Leifsonia 
The genus Leifsonia consists of rod shaped, Gram-positive bacteria, where some species can 
form filament structures. The colonies formed are normally circular and often have a white to 
light yellow colour (figure 5A). Members of the genus Leifsonia occur in different habitats, and 
they are often found on plants or in soil. Many different unnamed or preliminarily identified 
organisms exhibiting high 16S rRNA gene sequence similarities to the identified Leifsonia 
species have been discovered in various aquatic environments (Goodfellow et al., 2012, p. 907-
909). Table 1 shows the biological classification of Leifsonia with the data provided by 
Marbank. 
 
Figure 5: The bacteria cultivated in this thesis. A) Bacteria of the genus Leifsonia streaked on FMAP agar plate. 
B) Bacteria of the genus Polaribacter streaked on FMAP agar plate. Photo: Marte Jenssen. 
1.4.2.2 The genus Polaribacter  
Bacteria of the genus Polaribacter grow as rods, curved rods or as filaments. They are 
nonmotile, Gram-negative, heterotrophic and aerobic. Some of the species are psychrophilic or 
mesophilic, and grow well in marine media or media that have been supplemented with sodium 
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chloride. The colonies produce yellow, orange, salmon or pink pigments (figure 5B). All strains 
have been isolated from marine habitats, and some isolates have been able to grow at 
temperatures of 10°C or lower (Krieg et al., 2010, p. 255-256). Table 1 shows the biological 
classification of Polaribacter with the data provided by Marbank. 
Table 1: The biological classification of the bacteria used in this thesis: Polaribacter and Leifsonia. Information 
obtained from Marbank. 
Kingdom Bacteria Bacteria 
Phylum Bacteroidetes Actinobacteria 
Class Flavobacteria Actinobacteria 
Order Flavobacteriales Actinomycetales 
Family Flavobacteriaceae Microbacteriaceae 
Genus Polaribacter Leifsonia 
 
1.5 The One Strain-Many Compounds approach 
The OSMAC (One Strain-Many Compounds) approach is defined as: “Systematic alterations 
of easily accessible cultivation parameters in order to increase the number of secondary 
metabolites available from one microbial source” (Bode, Bethe, Höfs, & Zeeck, 2002, p. 619). 
Examples of parameters that can be altered are aeration, culture vessel, temperature, pH and 
media composition. Media composition can have a great impact on the production of microbial 
compounds (Bode et al., 2002), and small changes in the cultivation conditions have shown to 
alter the metabolic profile of various microorganisms (Höfs, Walker, & Zeeck, 2000). The 
genetic potential of microorganisms is substantial, but only a fraction of the biosynthetic 
diversity of the microbes is seen under normal laboratory cultivations. This is because, under 
routine laboratory cultivations, only a part of the biosynthetic genes of microbes are transcribed, 
which limits the chemical diversity of microbial compounds that are discovered (Schroeckh et 
al., 2009). Using the OSMAC approach, one tries to tackle this challenge by testing different 
cultivation conditions, hoping to trigger the organisms into expressing more and different genes 
(Marmann, Aly, Lin, Wang, & Proksch, 2014). Every biosynthetic pathway can be influenced 
at transcriptional, translational and protein level (enzyme inhibition or activation), resulting in 
a vast number of possible NPs (figure 6) (Bode et al., 2002). In nature, these regulations allow 




Figure 6: Illustration of the use of the OSMAC approach in an attempt to alter the biosynthetic pathways on 
transcriptional, translational and protein level, leading to a production of a variety of secondary metabolites. 
Inspired by reference (Bode et al., 2002, p. 621). 
One approach for overcoming the limitations of chemical diversity of microbes is mimicking 
their natural ecological situations. In nature, microorganisms co-exist in complex microbial 
communities. In these communities, the microorganisms rely on their production of bioactive 
secondary metabolites to defend themselves, to fight for the limited resources and to 
communicate with the other organisms. Co-cultivation of two or more different microorganisms 
in laboratory scale is one approach to mimic this. In 2014, Marmann and co-workers published 
a review named “Co-Cultivation – A Powerful Emerging Tool for Enhancing the Chemical 
Diversity of Microorganisms”, underlining the use of co-cultivation to increase the diversity of 
secondary metabolites produced by microorganisms during in vitro fermentation (Marmann et 
al., 2014). The approach has shown to enhance production of compounds that are not detected, 
or detected in smaller amounts, in cultures of single organisms (Slattery, Rajbhandari, & 




2 Workflow and background 
2.1 Workflow 
The work in this thesis was performed at Marbio, and their methods were the foundation of the 
experiments conducted. Marbio is a high throughput analytical platform within the area of NP 
drug discovery. Figure 7 shows an overview of the practical work for this thesis, and the 
background for the individual steps will be presented in the following sections.  
 
Figure 7: Workflow for the work conducted in this thesis. The bacteria were sampled and isolated by Marbank. 
The bacteria were cultivated using the OSMAC approach, the secreted secondary metabolites were extracted and 
the extracts were prefractionated using flash chromatography. The fractions were screened for antibacterial, 
biofilm formation inhibiting and anticancer activity. In the end, the active fractions were dereplicated. 
11 
 
The steps following dereplication are normally isolation, structure elucidation and bioactivity 
profiling of the compounds, but there is a long way from here to a commercially available 
product. The compound, now referred to as a “lead”, has to be optimised for its target through 
chemical synthesis of lead analogs, and has to go through pre-clinical and clinical trials to assess 
its safety and efficiency in treatment. These studies normally takes several years, and in the last 
phase the drug has to be approved by the appropriate authorities (e.g. Food and Drug 
Administration) and marketed (Rang, 2006, p. 43-45).  
2.2 Background 
2.2.1 Cultivation and extraction 
In this thesis, two Arctic Marine bacteria were cultivated under seven different cultivation 
treatments (utilising the OSMAC approach). Microorganisms produce a complex mixture of 
NPs, and these have to be extracted from the culture after cultivation (Seidel, 2012). In this 
project Diaion® HP-20, a polyaromatic resin, was used for the extraction of secondary 
metabolites from the bacterial cultures. The resin is recommended for the adsorption of solute 
molecules with molecular weights lower than 20-30 kilodaltons (Sterner, 2012). Diaion® HP-
20 is based on a styrene-divinylbenzene matrix and is used to adsorb hydrophobic compounds 
like biomolecules (Sigma-aldrich, n.d.-a).  
2.2.2 Prefractionation of extracts 
A crude extract consists of a complex mixture of compounds. To reduce the complexity of the 
extract, it is often necessary to fractionate it into fractions with compounds of similar traits, like 
polarity or molecular size (Sarker & Nahar, 2012b). Prefractionation of extracts to less complex 
mixtures enhances the hit rates by increasing the concentration of the active molecules 
(Gerwick & Moore, 2012). It is important not to generate too many fractions, so the target 
compound is spread to the degree where its quantity becomes too low to be detected or display 
activity in bioactivity screening (Sarker & Nahar, 2012b).  
Liquid chromatography (LC) is a technique that can be used to separate compounds in a 
mixture. The compounds are flushed through a column, and the interaction of the compounds 
with the stationary phase and the mobile phase determines the retention times of the different 
compounds (Reid & Sarker, 2012). In this study, flash chromatography was used for the 
prefractionation of the crude extracts. Benefits with flash chromatography is high sample 
capacity, and low costs (Bucar, Wube, & Schmid, 2013), but it is not expected to give the same 
resolution or reproducibility as high-performance LC (HPLC) (Stevens & Hill, 2009). The latter 
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point is however not too important in prefractionation, as a positive hit will nominate the 
fraction for isolation of the bioactive compound(s) using HPLC. The stationary phase used in 
this work was Diaion® HP-20SS, a polyaromatic adsorbent used for the separation of 
hydrophobic compounds and biomolecules (Sigma-aldrich, n.d.-b).  
2.2.3 Bioactivity screening 
At Marbio, extracts, fractions and pure compounds can be screened for different bioactivities, 
in both biochemical and cellular screenings. Examples of bioactivities that can be screened for 
are anticancer, antibacterial, biofilm formation inhibition, immunomodulation, anti-diabetes 
and antioxidant (Svenson, 2013). In this study, the flash fractions were screened for 
antibacterial, biofilm formation inhibiting and anticancer activities.  
2.2.3.1 Infectious diseases and antibacterial activity screening 
Infectious diseases are caused by pathogenic organisms. Bacteria are known agents of many 
human diseases, like tuberculosis which is caused by Mycobacterium tuberculosis (WHO, 
2017c) and abdominal problems caused by Escherichia coli (WHO, 2016b). According to the 
World Health Organization (WHO), antibiotic resistance is one of the biggest threats to global 
health today, and the levels of antibiotic resistance is rising to dangerously high levels in all 
parts of the world. Many infections, like tuberculosis and gonorrhoea are becoming harder to 
treat because the antibiotics used to treat them are becoming less effective. In addition to 
changing the use of the current antibiotics, the development of new antibiotics is necessary 
(WHO, 2016a). On the 27th of February 2017, WHO published the first ever list of antibiotic-
resistant “priority pathogens”, the bacteria that pose the greatest threat to human health. The 
organisms on the list were divided into three priorities: critical, high and medium. Among 
others, E.coli and Pseudumonas aeruginosa were placed as a critical priority, and 
Staphylococcus aureus were considered high priority (the complete list can be seen in table 2). 
The list was made in order to help prioritise the research and development of new antibiotic 




Table 2: WHO global priority list of antibiotic-resistant bacteria to guide research, discovery, and development 
of new antibiotics. Modified from reference (WHO, 2017b, p. 5).  
Priority Pathogen (Gram-stain) Resistance 
Critical Acinetobacter baumannii (G-) Carbapenem 
Pseudomonas aeruginosa (G-) Carbapenem 
Enterobacteriaceae* (G-) Carbapenem, 3rd generation cephlaosporin 
High Enterococcus faecium (G+) Vancomycin  
Staphylococcus aureus (G+) Methicillin, Vancomycin 
Helicobacter pylori (G-) Clarithromycin 
Campylobacter (G-) Fluoroquinolone 
Salmonella sp. (G-) Fluoroquinolone 
Neisseria gonorrhoeae (G-) 3rd generation cephalosporin, Fluoroquinolone 
Medium Streptococcus pneumoniae (G+) Penicillin 
Haemophilus influenza (G-) Ampicillin 
Shigella sp. (G-) Fluoroquinolone 
*Enterobacteriaceae include: Klebsiella pneumonia, Escherichia coli, Enterobacter sp., Serratia sp., Proteus sp., 
and Providencia sp., Morganella sp. 
The method used in this thesis for the antibacterial activity screening is based on the EUCAST 
(The European Committee on Antimicrobial Susceptibility Testing) discussion document E.Dis 
5.1 (EUCAST, 2003). The antibacterial activity of the fractions was tested on five known 
human pathogens: S.aureus, E.coli, Enterococcus faecalis, P.aeruginosa and Streptococcus 
agalactiae.  
2.2.3.2 Biofilm related infections and biofilm formation inhibiting activity screening 
Many types of bacterial infections are biofilm-related. Known examples are cystic fibrosis lung 
infection, chronic wounds and implant associated infections. These types of infections are a 
significant cause of morbidity and mortality. Biofilms are more tolerant to antibiotics and 
immune responses, compared to bacteria in planktonic form, which often lead to chronic 
infections (Wilkins, Hall-Stoodley, Allan, & Faust, 2014; Wu, Moser, Wang, Høiby, & Song, 
2014). Staphylococci are common cases of infections that have biofilm production as an 
important virulence factor. Production of biofilm is dependent on the synthesis of 
polysaccharide intracellular adhesin (PIA), and the enzymes involved in PIA synthesis are 
encoded by the ica operon. Biofilm production is significantly increased in the presence of 
glucose (Agarwal & Jain, 2013; Cafiso et al., 2004).  
The fractions produced in this thesis was screened for biofilm formation inhibiting activity 
against Staphylococcus epidermidis, in a spectrophotometric assay. This type of 
14 
 
spectrophotometric screening, using crystal violet to dye the biofilm, is a common method for 
measuring biofilm production and inhibition (Martínez Díaz et al., 2015; O'Toole, 2011), see 
figure 8. 
 
Figure 8: Biofilm dyed with crystal violet in biofilm formation inhibiting screening. The red field indicates 
inhibition of biofilm formation. Photo: Marte Jenssen. 
2.2.3.3 Cancer and anticancer activity screening 
In 2012, 14.1 million new cancer cases were diagnosed and 8.2 million people died from cancer. 
By the year 2025 it is expected that 19.3 million new cancer cases will be diagnosed each year, 
meaning that this is an increasing problem. The most common kinds of cancer are lung, breast, 
colorectal, stomach and liver cancer (WHO, 2013; WHO 2017a). Cancer is a term for a large 
group of diseases and is one of the leading causes of death. It is the uncontrolled growth of cells 
that can invade and spread to distant sites of the body (WHO, 2017a).  
In this thesis, fractions were screened for anticancer activity in an Aqueous One Solution Cell 
Proliferation assay, often called the MTS reduction assay. Proliferation assays are used to 
measure cell growth over time and measure the effects of compounds on the cell growth. The 
Aqueous One Solution contains a tetrazolium salt (yellow colour), called MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt). 
Only metabolically active/living cells are able to reduce the salt to a formazan product, which 
has a dark purple colour (see figure 9). The amount of surviving cells is proportional with the 
level of formazan product produced (Promega, 2012). Formazan absorbs radiation at 490 nm, 




Figure 9: Microtiter plate with human melanoma cancer cells (A2058), after incubation with Aqueous One 
Solution. The red field indicates dead cancer cells that are unable to reduce MTS (yellow colour) to formazan 
(dark purple colour). Photo: Marte Jenssen. 
2.2.4 Dereplication 
Dereplication is an important step in the bioprospecting pipeline. The goal of dereplication is 
to identify and avoid further work on active substances that are already known. An efficient 
dereplication procedure should be incorporated early in the pipeline, to minimise the efforts put 
into the sample (Perez-Victoria, Martin, & Reyes, 2016). At Marbio, the bioactivity data is used 
to guide the dereplication process, so fractions with confirmed bioactivity are nominated for 
dereplication. Through this work, the research group seeks to evade replication of work that has 
previously been conducted, and can instead focus on finding novel compounds, or known 
compounds with novel bioactivities. One of the difficulties with the dereplication process is the 
presence of so-called pan assay interfering compounds (PAINS), which are compounds that 
have broad and non-specific bioactivities and often give false positives in bioactivity 
screenings. Some of these compounds are well known and investigated, and because of their 
non-specific activity, they are not interesting with regards to drug discovery (Baell & Holloway, 
2010; Camp, Davis, Evans-Illidge, & Quinn, 2012). The field of PAINS has been extensively 
studied throughout the years (Aldrich et al., 2017; Baell & Holloway, 2010; Bisson et al., 2016), 
and is obviously a great problem in numerous screening programs. Through dereplication, the 
presence of these types of compounds can be detected and the sample can be removed from the 
pipeline (Hansen & Andersen, 2016).  
In this study, an Ultra-Performance-LC-Quadrupole-Time-of-Flight Mass Spectrometer 
(UPLC-QToF-MS) was used for the dereplication. As a simplified description, the MS can be 
divided into five parts: The sample inlet, ion source, mass analyser, detector and the data 
system. The sample inlet is where the sample is introduced to the system. In the system used in 
this study the sample was introduced in liquid form, as it elutes from the UPLC column. In the 
ion source the sample molecules are converted into gas phase ions. There are several different 
ionisation methods, and in this study electrospray ionisation (ESI) was used: The sample is 
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sprayed out of a fine capillary with high voltage potential, charged droplets are expelled into 
the ionisation chamber, where they are subjected to a drying gas (nitrogen) which evaporates 
the solvent. The evaporation continues until solvent-free sample ions are left in gas phase. ESI 
can be used to produce both positive and negative ions. The ionised sample is then moved into 
the mass analyser, where the ions are separated according to their mass-to-charge (m/z) ratios. 
As with ion sources, there are several different mass analysers. In this study, the Time-of-Flight 
(ToF) mass analyser was applied. ToF is based on the velocities of the ions, which in turn 
depends on their masses. If two ions are created at the same time, with the same energy, the 
lighter ion will travel faster than the heavier ion, and hit the detector faster. The detector is an 
ion counter, which produces a current that is proportional to the number of ions that strikes it. 
The signal from the detector is transferred to a recorder, that sends the information to the 
computer system, where the mass spectrum is produced (Lampman, Pavia, Kriz, & Vyvyan, 
2010, p. 418-434).  
It is common to couple the MS to a liquid chromatography (LC) unit, and one of the most used 
hyphenated techniques today is High-Performance LC (HPLC)-MS. When coupling a HPLC 
(separation technique) to a MS (analytical technique) the sample can be separated on the 
column, and then analysed based on their mass spectral data. The MS gives information about 
the molecular weight and the fragmentation pattern of the molecules (Sarker & Nahar, 2012a). 
In this study, the MS was coupled to a UPLC system. The active fractions from the bioactivity 
screenings were compared to the inactive fractions, in order to identify compounds only present, 
or present at a higher concentration, in the active fraction. Possible elemental compositions 
were calculated and used to search databases like The Dictionary of Marine Natural Products. 





Figure 10: The components of a LC-MS system, inspired by reference (Silverstein, Webster, & Kiemle, 2005, p. 





3 Aim of the thesis  
The overall aim of this thesis was to investigate how altering cultivation parameters affected 
the production of bioactive fractions from cultures of two Arctic marine bacteria. The three key 
objectives were to: 
1. Cultivate the two bacteria under seven different cultivation treatments 
2. Screen the fractions from the bacterial cultures for antibacterial activity, inhibition of 
biofilm formation and anticancer activity 




4 Materials and methods 
4.1 Sampling and storage 
Materials 
Table 3: The products/equipment used in sampling and storage. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Polaribacter sp. M09B074 Marbank, Institute of Marine Research 
(Norway) 
Leifsonia sp. M10B719 Marbank, Institute of Marine Research 
(Norway) 
Difco Marine Broth 279110  Becton, Dickinson and Company (New 
Jersey, USA) 
Peptone from casein, 
enzymatic digest 
82303 Sigma-Aldrich (Missouri, USA) 
Filtered sea water 5 µm pore size, ceramic membrane 
filter 0.2 µm, UV (Ultra Violet) filter 
Norwegian College of Fishery Science, 
UiT (Norway) 
Glycerol  G5516 Sigma-Aldrich (Missouri, USA) 
Milli-Q Ultrapure water  Merck KGaA (Germany) 
Sanyo Labo Autoclave   Sanyo Electric Co. (Japan) 
Stuart Heat Stir SB162  Stuart Equipment (UK) 
 
Method 
Two marine bacterial strains from the Marbank collection were used in this project; M09B074 
from the genus Polaribacter and M10B719 from the genus Leifsonia. The bacteria will be 
abbreviated PB for Polaribacter and LS for Leifsonia throughout the thesis. PB was isolated 
from an invertebrate of the family Sabellidaet, collected the 17th of May 2009 in the Barents 
Sea, diving at Bjørnøya (74.3737N, 19.1984E). LS was isolated from the intestine/stomach of 
a hagfish (Myxine glutinosa), collected the 16th of April 2010 in the Norwegian Sea region on 
a benthic trawl in Hadselfjorden (68.5025N, 15.0046E). The bacteria were classified down to 
genus level by Marbank, based on 16S rDNA analysis (species not determined).  
The isolates were stored in FMAP medium with 30% glycerol at -80°C. FMAP medium was 
prepared with 15 g/L Difco Marine broth and 5 g/L peptone in filtered seawater and Milli-Q 
Ultrapure water (MQ) with the ratio 3:7. Glycerol was added to the FMAP medium, and the 
solution was autoclaved (120 minutes, 121°C). The bacterial stock was prepared by plating the 
bacteria (from freeze stock isolates stored at -80°C), followed by incubation for 3-7 days at 
10°C. A single colony was picked and transferred to 5 mL FMAP medium and incubated at 
10°C for 2-3 days at 300 rpm (revultions per minute). From the culture, 500 µL was transferred 
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to cryo tubes together with 1 mL of FMAP with 30% glycerol. The isolates were stored at -
80°C. 
4.2 Preparation of cultivation media 
Materials 
Table 4: The products/equipment used in the preparation of cultivation media. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Sea salts S9883 Sigma-Aldrich (Missouri, USA) 
Malt extract 70167 Sigma-Aldrich (Missouri, USA) 
Yeast extract Y1625 Sigma-Aldrich (Missouri, USA) 
Peptone from casein, enzymatic digest 82303 Sigma-Aldrich (Missouri, USA) 
Iron(II) sulfate heptahydrate 1.03965 Merck KGaA (Germany) 
Potassium bromide 221864 Sigma-Aldrich (Missouri, USA) 
Dextrose D9434 Sigma-Aldrich (Missouri, USA) 
Casein hydrolysate 22090 Sigma-Aldrich (Missouri, USA) 
Potassium chloride 1.04935 Merck KGaA (Germany) 
Potassium dihydrogen phosphate 1.04871 Merck KGaA (Germany) 
Corn flour  Risenta AB (Sweden) 
Sodium nitrate S5506 Sigma-Aldrich (Missouri, USA) 
Magnesium sulphate heptahydrate 63138 Sigma-Aldrich (Missouri, USA) 
Milli-Q Ultrapure water  Merck KGaA (Germany) 
Sanyo Labo Autoclave   Sanyo Electric Co. (Japan) 
Stuart Heat Stir SB162  Stuart Equipment (UK) 
 
Method 
LS and PB were cultivated in four different media. The media composition with relative 
nutritional levels are displayed in table 5. All media were prepared with MQ and autoclaved for 




Table 5: Contents of the media used for cultivation of PB and LS. The relative nutritional levels of the different 
media are included. The two high nutrition media used, DVR_1 and DVR_2, are the same except for the addition 
of iron(II) sulphate heptahydrate and potassium bromide to DVR_2. 
Media names Nutritional level Chemical Amount 
DVR_1 High Sea salts 40.0 g/L 
 
 Malt extract 6.667 g/L 
 
 Peptone from casein, enzymatic digest 11.111 g/L 
 
 Yeast extract 6.667 g/L 
DVR_2 High Sea salts 40.0 g/L 
 
 Malt extract 6.667 g/L 
 
 Peptone from casein, enzymatic digest 11.111 g/L 
 
 Yeast extract 6.667 g/L 
 
 Iron(II) sulphate heptahydrate (8 g/L stock) 0.0444 g/L 
 
 Potassium bromide (8 g/L stock) 0.0444 g/L 
DSGC Intermediate Dextrose 4.0 g/L 
 
 Casein hydrolysate 3.0 g/L 
  Sea salts 40.0 g/L 
Corn flour medium Low Corn flour 1.0 g/L 
 
 Sea salts 40.0 g/L 
 
 Sodium nitrate 3.0 g/L 
 
 Potassium dihydrogen phosphate 0.75 g/L 
 
 Potassium chloride 0.25 g/L 
 
 Magnesium sulphate heptahydrate 0.25 g/L 
 
4.3 Seven cultivation treatments of the marine bacteria 
Materials 
The four different media described in table 5 were used for cultivation of the marine bacteria 
LS and PB. 
Table 6: The products/equipment used in the seven cultivation treatments of the marine bacteria. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Polaribacter sp. M09B074 Marbank, Institute of Marine Research 
(Norway) 
Leifsonia sp. M10B719 Marbank, Institute of Marine Research 
(Norway) 
Infors HT Multitron Pro  Infors HT (Switzerland) 
Sanyo Labo Autoclave   Sanyo Electric Co. (Japan) 
Branson 3510 Ultrasonic 
Cleaner 
 Emerson Industrial Automation 
(Missouri, USA) 
Herasafe biological safety 
cabinet 







Both bacteria were grown under seven different cultivation treatments, named cultivation 
treatment 1 - cultivation treatment 7 (C1-C7) (table 7). For each treatment, the bacteria were 
cultivated in four 1 L Erlenmeyer culture flasks with 250 mL medium (unless stated otherwise) 
in each flask. Preparation of the cultures was performed in a class II safety cabinet. To each 
culture flask, 370 µL of bacterial stock (See section 4.1 “Sampling and storage”) was added. 
The flasks were sealed with aluminium foil during the cultivation. In the following section, the 
different cultivation treatments will be described with greater detail. Media controls (MCs) 
were also prepared for DVR_1, DVR_2, DSGC and corn flour medium, with 250 mL medium.  
Table 7: Overview of the cultivation parameters used for the seven different cultivation treatments (C1-C7) that 
were conducted on PB and LS.  
Cultivation 
treatment 
Medium Additional altered 
parameters 




10°C, 140 rpm 8 
C2 DVR_2 
 
10°C, 140 rpm 8 
C3 DVR_1 Co-cultivation 10°C, 140 rpm 8 as monocultures,  
4 days as co-cultures 
C4 DVR_1 Cold-treatment 1-10°C, no shaking during 
cold treatment 
4°C, 140 rpm during storage 
12 days before cold-
treatment,  




10°C, 140 rpm 14 
C6 DSGC Addition of dead 
bacteria 
10°C, 140 rpm 8 days before addition,  
6 days after addition 
C7 Corn flour 
 
10°C, 140 rpm 19 
 
4.3.1 Normal conditions: C1, C2, C5 and C7 
The cultivation treatments C1, C2, C5 and C7, did not have any additional altered parameters, 
but different media were used for the different cultivations (table 8). The bacterial cultures were 
incubated at 10°C with 140 rpm shaking. The incubation time of the cultures, before adding 
resin, varied. This variation was based on the time it took to obtain a visually dense bacterial 
culture (see table 8). Because of low density, eight culture flasks were made with corn flour 




Table 8: Time of incubation for the cultures without any additional parameters altered (C1, C2, C5 and C7). The 
relative nutritional levels of the different media are included. 
Cultivation 
treatment 
Medium Level of nutrition of media 
(relative) 
Time of incubation before 
addition of resin (days) 
C1 DVR_1 High 8 
C2 DVR_2 High 8 
C5 DSGC Intermediate 14 
C7* Corn flour Low 19 
*The cultures prepared with corn flour medium (C7) were prepared with a total volume of 2000 mL, double of all 
the other cultures. 
4.3.2 Co-cultivation: C3 
In treatment C3, the two strains were co-cultivated. The cultures were first grown as 
monocultures in DVR_1 medium, until dense cultures were obtained. Then (8 days after starting 
cultivation) 1% of PS was added to the LS, and reverse. The mixed cultivation continued for 4 
days before resin was added. The cultures were kept at 10°C and 140 rpm for the entire 
cultivation. 
4.3.3 Cold-treatment: C4 
Both strains, grown in the DVR_1 medium, were cold treated by moving the cultures in and out 
of a -20°C freezer room (C4). Before starting the cold treatment, the cultures were grown for 
12 days at 10°C and 140 rpm (dense cultures obtained). In the freezer room, the culture 
temperature was decreased to ~1-2°C. The cultures were then placed in room temperature 
(~21°C), where the temperature was increased to 10°C before putting them back into -20°C. In 
total, ten rounds in and out of the freezer room was conducted over 3 days. During the cold-
treatment the cultures were not shaken. The cultures were incubated at 4°C and 140 rpm 
overnight during the cold-treatment period. Resin was added on the last day of cold-treatment. 
After adding resin, the cultures were incubated at 10°C and 140 rpm, until extraction.  
4.3.4 Cultivation with dead marine bacteria: C6 
For cultivation treatment C6, both strains were cultivated in DSGC medium for 8 days, before  
dead Arctic marine bacteria, Leeuwenhoekiella sp. (Marbank collection ID: M09W024) grown 
in M19 medium was added to the cultures (contents of the M19 medium are listed in Appendix 
1). The bacteria was killed by first autoclaving (121ºC for 120 minutes), followed by sonication 
for 10 minutes. Dead bacteria, 1% of the total culture volume, was then added to the cultures. 
The cultures were incubated for 6 days, before resin was added. For the entire time of 
cultivation, the cultures were kept at 10°C and 140 rpm. 
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4.4 Extraction from the bacterial cultures 
Materials 
Table 9: The products/equipment used in the extraction of secondary metabolites. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Methanol 34860 Sigma-Aldrich (Missouri, USA) 
Agar A1296 Sigma-Aldrich (Missouri, USA) 
Difco Marine Broth 279110  Becton, Dickinson and Company 
(New Jersey, USA) 
Peptone from casein, 
enzymatic digest 
82303 Sigma-Aldrich (Missouri, USA) 
Filtered sea water 5 µm pore size, ceramic 
membrane filter 0.2 µm, UV filter 
Norwegian College of Fishery 
Science, UiT (Norway) 
Diaion® HP-20 13607 Sigma-Aldrich (Missouri, USA) 
Milli-Q Ultrapure water  Merck KGaA (Germany) 
Cheesecloth filter, fine mesh  Dansk Hjemmeproduktion 
(Denmark) 
Whatman® qualitative filter 
paper, grade 3 
1003-090 Sigma-Aldrich (Missouri, USA) 








For extraction of the secreted secondary metabolites, Diaion® HP-20 resin was added to the 
cultures, 40 g/L medium. Before addition, the resin was activated by soaking it in 100% 
methanol for minimum 30 minutes, before it was washed extensively with MQ. Small amounts 
of MQ was used to add the resin to the cultures. All cultures were incubated with resin for 3 
days before the extraction was performed. Cultures and controls were extracted using the same 
method. Before starting the extraction, a 400 µL sample was taken from the cultures (not MCs) 
as a DNA storage sample (see 4.4.1 “Treatment of DNA storage samples”). To check for 
contamination, the cultures were plated on FMAP agar before extraction. The plates were stored 
at 10°C and checked for growth after a few days of incubation. FMAP agar was prepared with 
FMAP medium with 15 g/L of agar added before autoclaving.  
The cultures with resin were vacuum filtered using cheesecloth filters. To remove the culture 
medium, it was poured over the filter with the resin beads remaining in the culture flask. Next, 
the resin was washed with 200 mL of MQ and filtered. To extract the secondary metabolites 
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from the resin, 100 mL of methanol was added to the resin followed by incubation for minimum 
1 hour with gentle shaking. After incubation the extract was filtrated through a Whatman filter. 
Methanol was added again, 100 mL, to the resin for another round of extraction, with minimum 
15 minutes of incubation. The extract was again filtrated, into the same flask as the last 
extraction. From the extract, a 400 µL sample was taken for a MS analysis storage sample. The 
MS sample was stored at -20°C. The extracts were dried under pressure at 40°C using the 
rotavapor, and stored at -20°C until use. A total of 14 extracts were made, seven from each 
bacterium (C1-C7). The extracts were named according to their bacterium (PB or LS) and 
cultivation treatment (C1-C7). Example: LS with cultivation treatment C1 was named LSC1. 
4.4.1 Treatment of DNA storage samples 
Before extraction, 400 µL of culture was transferred to an Eppendorf tube and centrifuged for 
5 minutes at 13 000 rpm. The supernatant was decanted, and the pellet washed with 1 mL 
autoclaved MQ. The sample was again centrifuged for 5 minutes at 13 000 rpm, and the 
supernatant decanted. The pellet was stored at -20°C for possible identity check of the cultures.  
4.5 Prefractionation of the extracts 
Materials 
Table 10: The products/equipment used in the prefractionation of extracts. 
Product/Equipment  Product ID/Equipment 
specifications 
Distributor (Country) 
Methanol 34860 Sigma-Aldrich (Missouri, USA) 
Acetone 34850 Sigma-Aldrich (Missouri, USA) 
Diaion® HP-20SS  13615-U Sigma-Aldrich (Missouri, USA) 
Milli-Q Ultrapure water  Merck KGaA (Germany) 
Rotary Evaporator (Rotavapor) Laborota Heidolph Instruments GmbH & Co 
(Germany) 
Biotage® HPFC SP4 Flash 
Purification System 
 Biotage (Sweden) 
Biotage® SNAP Cartridge KP-
Sil (10 g) 
FSK0-1107-0010 Biotage (Sweden) 
Universal Shaker SM 30  Edmund Bühler GmbH (Germany) 
 
Method 
Prefractionation of the extracts, using the Biotage Flash system, was performed to produce six 
fractions from each extract (MCs were not fractionated). The extracts were dissolved in 90% 
methanol before adding 2 g of Diaion® HP-20SS column material. If an extract consisted of 
more than 1.5 g material, it was divided in two, and 2 g column material was added to each 
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part. Further, the extracts with column material was dried using the rotavapor. When the sample 
was completely dry it was added to a prepacked SNAP column (see 4.5.1 “Preparation of SNAP 
columns”), and run on the Biotage system with MQ, methanol and acetone mobile phases (table 
11). The flow rate was 12 mL/minute and each fraction was collected for two minutes. From 
the prefractionation, 27 tubes were obtained. These tubes were pooled, resulting in six fractions 
(table 12). The fractions are abbreviated fraction 1-fraction 6 (F1-F6) throughout the thesis. 
Table 11: Mobile phase gradient used with the Biotage flash system for the prefractionation of the extracts.  
Time (minutes) MQ (%) Methanol (%) Acetone (%) Fraction number 
0-6 95 5 0 1-3 
6-12 75 25 0 4-6 
12-18 50 50 0 7-9 
18-24 25 75 0 10-12 
24-36 0 100 0 13-18 
36-42 0 50 50 19-20 
42-54 0 0 100 21-27 
 
Table 12: The 27 flash tubes were pooled, resulting in six fractions (F1-F6). 
Fraction Flash tube 
F1 1, 2, 3 
F2 4, 5, 6 
F3 7, 8, 9 
F4 10, 11, 12 
F5 13, 14, 15 
F6 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 
 
4.5.1 Preparation of SNAP columns 
The SNAP 10 g cartridges used in prefractionation were pre-packed with Diaion® HP-20SS 
column material (adsorbent); 6.5 g of the adsorbent was pretreated by soaking in methanol for 
minimum 20 minutes, then washing extensively with MQ. The column material was added to 




4.6 Stock solution preparation 
Materials 
Table 13: The products/equipment used in stock solution preparation. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Dimethyl Sulfoxide D4540 Sigma-Aldrich (Missouri, USA) 
Milli-Q Ultrapure water  Merck KGaA (Germany) 
Syncore® Polyvap  Büchi (Switzerland) 
Heto PowerDry® PL9000 
Freeze Dryer 




After prefractionation, the fractions were dried using Polyvap and dissolved in dimethyl 
sulfoxide (DMSO) with concentrations varying between 10 mg/mL to 80 mg/mL (depending 
on the amount of material after drying). The fractions were stored at -20°C until further use. 
From the MC extracts, stock solutions with a concentration of 40 mg/mL in DMSO were 
prepared and stored at -20°C. For bioactivity screening, deep-well plates (DWPs) were prepared 
with all the fractions and MCs. The fractions and MCs were frozen in the DWPs, and freeze-
dried until completely dry. The fractions were dissolved in autoclaved MQ with 2.5% DMSO 
to a concentration of 1 mg/mL. The plates were stored at -20°C when not in use, and at 4°C 
when in use (maximum one week). When screening for different bioactivities, the fractions 
were taken from these plates (termed test-DWP throughout the thesis).  
4.7 Bioactivity screening of fractions and media controls 
All fractions and MCs were screened for antibacterial activity, inhibition of biofilm formation 
and anticancer activity. The work was conducted in a class II safety cabinet. First, all fractions 
were screened using one concentration (50 µg/mL) in the primary screening. The active 
fractions were retested in a secondary screening with several concentrations, to confirm activity 
and to check for dose-response activity. All screenings were performed in 96-well microtiter 
plates, and absorbance measurements were used for evaluation of results. The different 




4.7.1 Antibacterial activity screening 
Materials 
Table 14: The products/equipment used in the antibacterial activity screening. 
Product/Equipment  Product ID/Equipment 
specifications 
Distributor (Country) 
Mueller Hinton broth (MH) 275730 Becton, Dickinson and Company 
(New Jersey, USA) 
Brain heart infusion broth 
(BHI) 
53286 Sigma-Aldrich (Missouri, USA) 
Sodium chloride S5886 Sigma-Aldrich (Missouri, USA) 
Blood agar plates  University hospital of North 
Norway (UNN), (Norway) 
Luria-Bertoni plates  University hospital of North 
Norway (UNN), (Norway) 
Glycerol G5516 Sigma-Aldrich (Missouri, USA) 
Gentamycin (10 mg/mL) A 2712 Merck KGaA (Germany) 
Milli-Q Ultrapure water  Merck KGaA (Germany) 
Staphylococcus aureus ATCC® 25923 LGC Standards (UK) 
Escherichia coli ATCC® 25922 LGC Standards (UK) 
Enterococcus faecalis ATCC® 29212 LGC Standards (UK) 
Pseudomonas aeruginosa ATCC® 27853 LGC Standards (UK) 
Streptococcus agalactiae ATCC® 12386 LGC Standards (UK) 
Heated Incubator MIR-262  Panasonic Healthcare (Japan) 
Incubator Unimax 1010   Heidolph Instruments GmbH & 
Co (Germany) 
Victor Multilabel Counter   Perkin Elmer (Massachusetts, 
USA) 
Herasafe biological safety 
cabinet 




4.7.1.1 Preparation of the test bacteria 
The antibacterial activity of the fractions and MCs was screened against five bacterial test 
strains (table 15). The test bacteria were stored in the same medium that they were grown in 
with 10% glycerol at -80°C. When in use, the bacteria were kept on blood agar plates (maximum 
1 month), with re-streaks every second week for maintenance of the bacteria. When the 
screening was to be performed, a scoop of bacteria was transferred into 8 mL growth medium, 
and allowed to grow overnight at 37°C. From the overnight cultures, 2 mL was transferred into 
25 mL fresh cultivation medium. The cultures were incubated with shaking at 37°C for the time 
period stated in table 15 to reach 0.5 McFarland turbidity (1.0 x 108 bacteria/mL). After 




Table 15: The test bacteria used in the antibacterial activity screening, their cultivation media, and incubation 
time needed to reach 0.5 McFarland turbidity.  
Bacterial strain Medium for cultivation Incubation time (second day) 
S.aureus MH 2.5 h 
E.coli MH 1.5 h 
E.faecalis BHI  1.5 h 
P.aeruginosa MH 2.5 h 
S.agalactiae BHI 1.5 h 
 
4.7.1.2 Preparation of the 96-well microtiter plates  
Fractions and MCs were taken from the test-DWP and diluted with autoclaved MQ to the 
chosen concentrations. In the primary screening, all fractions and MCs were screened at a final 
concentration of 50 µg/mL (in duplicates). In the secondary screening, the active fractions were 
screened at 50, 25, 10 and 1 µg/mL (in duplicates). From the fraction/MC, 50 µL was 
transferred to a 96-well microtiter plate, one plate per bacteria to be tested. From the prepared 
1:1000 bacterial solutions, 50 µL was added to the fractions/MC, making the total dilution of 
the bacterial solution in the screening 1:2000 (from 0.5 McFarland turbidity). Positive and 
negative controls for the screening were also included on the plates. Negative control was 
prepared with 50 µL medium and 50 µL autoclaved MQ. Positive control was prepared with 50 
µL autoclaved MQ and 50 µL bacterial suspension. All the plates were incubated at 37°C for 
20-24 hours. 
4.7.1.3 Reading of plates and evaluation of results 
After 20-24 hours of incubation at 37°C, the plates were first checked visually for growth 
inhibition. Absorbance (Abs) of the microtiter plates was then measured at 600 nm. Software 
used was WorkOut 2.5 (dasdaq, England). Threshold Abs600 values were used to define the 
fractions either active, questionable or inactive: 
 Active ≤0.05 
 Questionable 0.05-0.09 
 Inactive ≥0.09 
Fractions deemed active were retested in the secondary screening. 
4.7.1.4 Gentamycin control 
Gentamycin controls were performed routinely, as a control for normal growth of the bacteria, 
and as a control for the assay. The control was performed in final concentrations ranging from 
16 to 0.01 µg/mL in order to determine the minimum inhibitory concentration (MIC) of 
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gentamycin for the test bacteria. In a 96-well microtiter plate, 50 µL gentamycin control was 
added to 50 µL bacterial solution. The plate was incubated overnight at 37°C. The MIC values 
were evaluated visually by looking for growth inhibition. If the MIC values for gentamycin 
were more than one titer step outside of the reference values (table 16), the screening had to be 
run again.  
Table 16: Reference MIC values and CFU ranges for the test bacteria used in the antibacterial screening. 
Test bacteria Reference MIC values for gentamycin (µg/mL) CFU ranges 
S.aureus 0.25 0.5-3x105 CFU/mL 
E.coli 0.50 0.5-3x105 CFU/mL 
E.faecalis 10.00 0.5-3x105 CFU/mL 
P.aeruginosa 0.50 3-7x104 CFU/mL 
S.agalactiae 4.00 0.5-3x105 CFU/mL 
 
4.7.1.5 Control of colony forming unit 
Control of colony forming unit (CFU) were also performed routinely, as a control for steady 
growth of the bacteria. After 1.5/2.5 hour incubations on the second day of the screening, the 
bacterial solution was diluted in 0.9% sodium chloride solution, first 1:100 times two, and then 
1:10 times two. The two last dilutions (1:100 000 and 1:1 000 000) were plated in two parallels 
on Luria-Bertoni plates with 100 µL culture, and incubated overnight at 37°C. The number of 
colonies was counted, and the CFU was calculated and checked against the standard CFU 




4.7.2 Biofilm formation inhibiting activity screening 
Materials 
Table 17: The products/equipment used in the biofilm formation inhibiting activity screening. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Tryptic soy broth (TSB) 1.05459 Merck KGaA (Germany) 
Dextrose (Glucose) D9434 Sigma-Aldrich (Missouri, USA) 
Ethanol 24106 Sigma Aldrich (Missouri, USA) 
Blood agar plates  University hospital (UNN) Tromsø, 
(Norway) 
Crystal violet 1.15940 Merck KGaA (Germany) 
Glycerol G5516 Sigma-Aldrich (Missouri, USA) 
Milli-Q Ultrapure water  Merck KGaA (Germany) 
Staphylococcus epidermidis ATCC 35984 University hospital (UNN) Tromsø, 
(Norway) 
Staphylococcus haemolyticus Clinical isolate 8-7A University hospital (UNN) Tromsø, 
(Norway) 
Heated Incubator MIR-262  Panasonic Healthcare (Japan) 
Incubator Unimax 1010   Heidolph Instruments GmbH & Co 
(Germany) 
Victor Multilabel Counter   Perkin Elmer (Massachusetts, USA) 
Herasafe biological safety 
cabinet 




4.7.2.1 Preparation of test bacteria  
The fractions were screened for biofilm formation inhibiting activity against S.epidermidis. 
S.haemolyticus was used as a control of a non-biofilm forming bacterium. Both bacteria were 
stored in tryptic soy broth (TSB) medium with 10% glycerol at -80°C. When in use, the bacteria 
were kept on blood agar plates (maximum one month), being re-streaked every second week. 
One scoop of each bacterium was inoculated in 5 mL of TSB and incubated overnight at 30°C. 
After overnight incubation, the cultures were diluted 1:100 in TSB with 1% glucose (inducer).  
4.7.2.2 Preparing 96-well microtiter plates 
Fractions and MCs were taken from the test-DWP and diluted with autoclaved MQ. In the 
primary screening, all fractions and MCs were screened at a final concentration of 50 µg/mL 
(in triplicates). In the secondary screening, the fractions were screened at 50, 25, 10 and 1 
µg/mL (in duplicates). From the test DWP with fractions and MCs, 50 µL was transferred to a 
96-well microtiter plate. From the bacterial suspension of S.epidermidis (in TSB with 1% 
glucose), 50 µL was added to all the wells with fractions or MCs. Positive control for the 
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screening was 50 µL S.epidermidis culture and 50 µL autoclaved MQ. Negative control for the 
screening was 50 µL S.haemolyticus culture and 50 µL autoclaved MQ. A medium blank with 
TSB and 1% glucose was also included in the screening, with 50 µL medium and 50 µL 
autoclaved MQ. The microtiter plates were incubated at 37°C overnight.  
After the overnight incubation, the plates were visually examined for growth inhibition to check 
that antibacterial activity was not misinterpreted as biofilm formation inhibiting activity. The 
bacterial suspension was then poured out of the plate, and the wells were rinsed with water. To 
fixate the biofilm to the bottom of the wells, the plates were incubated at 55°C for 1 hour. After 
fixation the biofilm was coloured, by adding 70 µL 0.1% crystal violet solution to all the wells, 
and incubated for 5 minutes. The crystal violet solution was then poured off and the plate was 
again rinsed with water. The plates were incubated again at 55°C for about 1 hour or until the 
plates were dry.  
4.7.2.3 Reading plates and evaluating results 
To all the wells, 70 µL 70% ethanol was added, and the plates were incubated for 10 minutes 
at room temperature. Absorbance was measured for the microtiter plates at 600 nm. Software 
used was WorkOut 2.5 (dasdaq, England). The fractions were considered active if the measured 




4.7.3 Anticancer activity screening 
Materials 
Table 18: The products/equipment used in the anticancer activity screening. 
Product/Equipment Product ID/Equipment 
specification 
Distributor (Country) 
Earle’s Minimal Essential 
Medium (E-MEM) with 20 mM 
HEPES 
F4315 Merck KGaA (Germany) 
Roswell Park Memorial 
Institute medium (RPMI) 1640 
FG 1383 Merck KGaA (Germany) 
Dulbecco's Modified Eagle 
Medium (D-MEM), high 
glucose, GlutaMAX™ 
Supplement, HEPES 
32430027 Thermo Fisher Scientific 
(Massachusetts, USA) 
Non-essential amino acids 
(NEA) (100x) 
K 0293 Merck KGaA (Germany) 
L-Alanyl-L-Glutamine (200 
mM) 
K 0302 Merck KGaA (Germany) 
Gentamycin (10mg/mL) A 2712 Merck KGaA (Germany) 
Sodium Bicarbonate solution 
(7.5%) 
L 1713 Merck KGaA (Germany) 
Sodium Pyruvate (100 mM) L 0473 Merck KGaA (Germany) 
CellTiter 96® Aqueous One 
Solution Reagent  
G358B Promega (Wisconsin, USA) 
Fetal Bovine Serum (FBS) S0115 Merck KGaA (Germany) 
A2058 ATCC® CRL-11147™ LGC Standards (UK) 
MRC-5 ATCC® CCL-171™ LGC Standards (UK) 
Trypsin (1:250) 27250018 Thermo Fisher Scientific 
(Massachusetts, USA) 
Triton™ X-100 T8787 Sigma-Aldrich (Missouri, USA) 
Sanyo CO2 Incubator MCO-
18AIC 
 Panasonic Biomedical (Japan) 
DTX 880 Multimode Detector   Beckman Coulter (California, 
USA) 
Herasafe biological safety 
cabinet 




All fractions were screened for anticancer activity against the human melanoma cancer cell line 
A2058. In the primary screening, all fractions were tested in one concentration to check for 
activity. The fractions that were considered active were subjected to secondary screening at 
different concentrations against A2058, and a normal human fibroblast cell line (MRC-5) as a 
control for toxicity.  
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4.7.3.1 Maintenance of the cell cultures 
A2058 was cultivated in D-MEM medium with additions, and MRC-5 was cultivated in E-
MEM with additions (table 19). The cell cultures were split when cell density was 70-80%, to 
maintain the cells in a monolayer. When splitting the cells the growth medium was discarded, 
and the cells were washed with phosphate-buffered saline (PBS) for about 1 minute before 
trypsinating (0.25% in PBS) for maximum 15 seconds (see Appendix 2 for preparation of PBS 
and trypsin solution). Trypsin was discarded and the cultures were incubated at 37°C for 3-6 
minutes. When the cells were detached from the bottom of the flask, the cells were resuspended 
in 10 mL growth medium. A new culture flask was prepared with fresh medium, and 
transferring sufficient amounts of resuspended cells to reach a cell density of 70 – 80% before 
the next round of splitting. The cells were kept at 37°C and 5% CO2.  
Table 19: Cultivation media (with additions) used for cultivating the different cell lines. RPMI-1640 was used 
when adding fractions to the cells. D-MEM was used when maintaining the A2058 cells in culture, and E-MEM 
was used when maintaining MRC-5 cells in culture. MRC-5 was included as a control for toxicity. 
RPMI-1640 D-MEM E-MEM 
10% FBS 10% FBS 10% FBS 
0.01 mg/mL Gentamycin 0.01 mg/mL Gentamycin 0.01 µg/mL Gentamycin 
1% L-Alanyl-L-Glutamine 1% L-Alanyl-L-Glutamine 1% L-Alanyl-L-Glutamine 
  1% NEAA 
  1% Sodium Pyruvat 
  1% Sodium bicarbonat 
 
For screening, 100 µL cell suspension was seeded out in 96-well microtiter plates. The 
resuspended cells that had been trypsinated were seeded with approximately 2000 cells per well 
(A2058) and 4000 cells per well (MRC-5). The cells were diluted in appropriate medium, to 
reach the wanted cell densities, and added to the microtiter plates. The plates were incubated 
for 24 hours at 37°C, 5% CO2.  
4.7.3.2 MTS cell proliferation assay, reading and evaluation of results 
After 24 hours of incubation, the cells were ready for the addition of fractions/MCs. The 
fractions and MCs were taken from the test-DWP and diluted in RPMI (table 19). In the primary 
screening, all fractions and MCs were screened with a final concentration of 50 µg/mL (in 
triplicates). In the secondary screening, the active fractions were screened at 50, 25, and 10 
µg/mL (in duplicates). Before fractions/MCs were added to the cells, the cell medium was 
removed. Then, 100 µL fraction/MC (diluted in RPMI) was added to the cells. Negative 
controls for the plates were made with RPMI medium. Cells treated with 0.5% triton were used 
as a positive control. The plates were further incubated for ~72 hours at 37°C and 5% CO2. 
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After 72 hours of incubation, 10 µL Aqueous One Solution was added to each well, and the 
plates were further incubated for 1 hour. Absorbance was measured at 485 nm, using the DTX 
880 Multimode Detector and the Multimode Analysis Software (Beckman Coulter, USA). Cell 
survival was calculated (equation 1). Fractions that gave cell survival of less than 50% were 






Equation 1: Calculation of cell survival (%) in MTS cell proliferation assay. Absorbance fraction (AbsF) is the 
average of Abs485 measured in wells with fractions, Absorbance positive control (AbsP) is the average of Abs485 
measured in wells with positive control, and Absorbance negative control (AbsN) is the average of Abs485 measured 
in wells with negative control. 
4.8 Dereplication of active fractions from bioactivity screening 
Materials 
Table 20: The products/equipment used in the dereplication of active fractions. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
HPLC glass vials  Waters (Massachusetts, USA) 
VION ® IMS QToF  Waters (Massachusetts, USA) 
Acquity UPLC PDA Detector  Waters (Massachusetts, USA) 
Acquity UPLC Column Manager  Waters (Massachusetts, USA) 
Acquity UPLC I-Class Sample 
Manager FTN 
 Waters (Massachusetts, USA) 
Acquity UPLC I-Class Binary 
Solvent Manager  
 Waters (Massachusetts, USA) 
ACQUITY UPLC BEH C18 
Column, 130Å, 1.7 µm, 2.1 mm X 
100 mm 
186002352 Waters (Massachusetts, USA) 
Methanol LC-MS Ultra 
CHROMASOLV® 
14262 Thermo Fisher Scientific 
(Massachusetts, USA) 
Milli-Q Ultrapure water  Merck KGaA (Germany) 
Formic acid 99% ULC/MS 069141 Biosolve B.V. (Netherland) 
LiChrosolv® Acetonitrile 
Hypergrade for LC-MS  
1.00029 Merck KGaA (Germany) 
 
Method 
The fractions that were deemed active in the secondary bioactivity screenings were further 
analysed using UPLC-QToF-MS. Before injection, the fractions were diluted 1:20 in 80% 
methanol and transferred to HPLC glass vials. The fractions were taken from the DMSO stock 
solutions (see section 4.6 “Stock solution preparation”). The injection volume used was 1 µL, 
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and the samples were run on the Acquity UPLC class system, with a C18 column, followed by 
the Vion IMS QToF. All samples were run on ESI+ mode, and complex samples were also run 
on ESI- mode. The following mobile phases were used: 
 Mobile phase A: MQ + 0.1% formic acid 
 Mobile phase B: Acetonitrile + 0.1% formic acid 
The UPLC gradient of the mobile phases is listed in table 21, and the ESI+/- parameters for the 
Vion IMS QToF are listed in table 22. 
Table 21: Mobile phase gradient of mobile phase A (MQ + 0.1% formic acid) and mobile phase B (Acetonitrile + 
0.1% formic acid) used on the Aquity UPLC system connected to the MS.  
Time (minutes) Flow rate (mL/minute) Mobile phase A (%) Mobile phase B (%) 
0 0.450 90 10 
12 0.450 0 100 
13.50 0.450 0 100 
 
Table 22: Parameters utilised for the Vion IMS QToF in ESI+ and ESI- during the dereplication process. 
Parameters ESI+/ESI- 
Mass range 50-2000 m/z 
Capillary voltage 0.80 kV 
Cone voltage 30 V 
Source temperature 120°C 
Desolvation temperature 450°C 
Cone gas flow 50 L/h 
Desolvation gas flow 800 L/h 
Low collision energy 6.0 eV 
High collision energy  15-45 eV 
Scan time 0.2 s 
 
The active fractions were compared to the inactive fractions eluted before and the inactive 
fractions eluted after the active fraction (from the prefractionation) to see if there were 
compounds only present, or present in higher concentrations, in the active fractions compared 
to the inactive ones. When a possible candidate responsible for the observed activity was 
detected, the software Waters UNIFI was used to calculate a possible elemental composition 
based on the accurate mass and the isotopic pattern of the compound. The calculated elemental 
compositions were used to search databases, primarily the Dictionary of Marine Natural 




5 Results  
5.1 Extraction from the bacterial cultures 
The two bacterial isolates, LS and PB, were grown under seven different cultivation treatments 
(see table 7). After cultivation, secreted secondary metabolites were harvested and extracted 
from the culture medium using Diaion® HP-20 resin and methanol, obtaining 14 extracts, seven 
from each isolate. The weight of the extracts varied between 400-3300 mg (figure 11). The 
weight was higher for the cultures grown in the high nutrition media DVR_1 and DVR_2 (C1-
C4). For treatment C1-C4, the extracts produced from the LS cultures weighed more than the 
PB counterparts, while the weight was quite similar for the two strains for the intermediate 
nutritional medium DSGC cultures (C5-C6) and the low nutrition corn flour medium cultures 
(C7). 
 
Figure 11: Weight of the extracts from the seven different cultivation treatments (C1-C7) prepared from A) LS and 
B) PB. The secreted secondary metabolites were harvested with Diaion® HP-20 resin, and extracted with 
methanol. The extracts were prepared from 1 L of bacterial culture, except for the two extracts from the corn flour 
cultures (C7) which were prepared from 2 L of bacterial culture.  
Extracts of the media controls (MCs) were prepared for each medium used (figure 12). The two 
high nutrition media DVR_1 and DVR_2 gave extracts with the highest weights, approximately 
890 mg from 250 mL of medium, while DSGC gave approximately 225 mg from the same 




Figure 12: Weight of media control extracts for each medium used in the cultivation of LS and PB. Media 
components were harvested with Diaion® HP-20 resin and extracted using methanol. The weight is based on 
extraction of 250 mL of medium. 
5.2 Prefractionation of the extracts 
The extracts were prefractionated using flash chromatography. Each extract was fractionated 
into six fractions, giving a total of 84 fractions for further bioactivity screening. Figure 13 and 
figure 14 show the weight of the fractionations from LS and PB, respectively. Generally, there 
was higher weight of the first three fractions (F1-F3) than in the last three (F4-F6), especially 
for F5 and F6 that had very low weights, ranging from 2-58 mg.  
 
Figure 13: Weight of the fractions (F1-F6) from the extracts made from the seven different cultivation treatments 
(C1-C7) of LS. The extracts were fractionated using flash chromatography with Diaion® HP-20SS columns and 




Figure 14: Weight of the fractions (F1-F6) from the extracts made from the seven different cultivations (C1-C7) 
of PB. The extracts were fractionated using flash chromatography with Diaion® HP-20SS columns and mobile 
phase gradient ranging from polar (MQ) to non-polar (acetone). 
5.3 Bioactivity screening of fractions and media controls 
In total, 84 fractions were prepared and screened for antibacterial activity, biofilm formation 
inhibiting activity and anticancer activity. No activity was observed for fractions 1, 2 or 3 (F1-
F3) for any extracts, so these will not be further mentioned. Table 23 shows a compilation of 
the results from the primary screenings for all the fractions F4-F6. Fractions deemed active in 
the primary screening were further tested in a secondary screening with different 
concentrations. At Marbio, cut-off values are used in the primary screenings to decide which 
fractions/extracts are interesting for further screening. In this project, the cut-off values were 
used as guidance and to limit the amount of samples to be further investigated. The cut-off 
values are listed under the results from the individual bioactivity screenings. In total, eight 
fractions were deemed active from LS, and six from PB after the primary screenings. Some of 
the fractions were active in more than one of the bioactivity screenings. None of the MCs 





Table 23: Results from the primary bioactivity screenings of the fractions (F4-F6) from the seven cultivations (C1-
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+ indicates active fraction, blank indicates not active fraction. Blue indicates activity in one screening, green 
indicates activity in several screenings. 
5.3.1 Antibacterial activity screening 
5.3.1.1 Primary screening 
All fractions were screened for antibacterial activity with a concentration of 50 µg/mL against 
five known human pathogenic bacteria: S.aureus, E.coli, E.faecalis, P.aeruginosa and 
S.agalactiae. Four fractions were deemed active with Abs600 levels of 0.05 or below (cut-off 





Table 24: Active fractions from the primary antibacterial activity screening, conducted on the fractions (50 µg/mL) 
obtained from the LS and PB cultures. Fractions were incubated with the test strains, S.aureus, E.coli, E.faecalis, 
P.aeruginosa and S.agalactiae for ~24 hours. Normal Abs600 values for the test strains when uninhibited: 
S.aureus 0.23-0.30, E.coli 0.35-0.40, E.faecalis 0.25-0.30, P.aeruginosa 0.46-0.56, S.agalactiae 0.19-0.23. 
Active fraction Abs600 Inhibited strain 
LSC6F5 0.05/0.04 E.faecalis / S.agalactiae 
PBC3F5 0.05 S.aureus 
PBC3F6 0.04 S.aureus 
PBC6F5 0.04 S.agalactiae 
 
5.3.1.2 Secondary screening 
The active fractions from the primary antibacterial activity screening were retested on the 
bacteria that they were active against with the following concentrations: 50, 25, 10, 1 µg/mL. 
Antibacterial activity was confirmed for all fractions, and for some of the fractions dose-
response activity could be observed. From LS, one fraction (LSC6F5) was active against both 
S.agalactiae and E.faecalis (figure 15). This fraction was active in the three highest 
concentrations against S.agalactiae, and against E.faecalis it displayed dose-response activity.  
 
Figure 15: Results from the secondary antibacterial activity screening of the active fraction obtained from LS. 
LSC6F5 with activity against A) S.agalactiae and B) E.faecalis, after ~24 hours incubation. The retest was 
conducted at 50, 25, 10 and 1 µg/mL.  
For PB, three fractions were retested and the activity was confirmed (figure 16). Two of the 
fractions originated from the same extract, PBC3, and were deemed active against S.aureus. 
PBC3F5 was active at the two highest concentrations, while PBC3F6 was active at the three 






Figure 16: Results from the secondary antibacterial screening of the active fractions obtained from PB: A) 
PBC3F5 with activity against S.aureus, B) PBC3F6 with activity against S.aureus and C) PBC6F5 with activity 
against S.agalactiae. The retest was conducted at 50, 25, 10 and 1 µg/mL and the incubation period was ~24 
hours. 
5.3.2 Biofilm formation inhibiting activity screening 
5.3.2.1 Primary screening 
All fractions were screened for inhibition of the biofilm formation of S.epidermidis, with the 
concentration 50 µg/mL. Fractions that gave Abs600 of 0.25 or lower were considered active. 
Before fixating the biofilm the bacterial cultures were checked for growth inhibition, and none 
of the active fractions seemed to influence the growth of S.epidermidis. One fraction with 
Abs600 of 0.26 was also included in further screening for biofilm formation inhibiting activity. 
Four fractions displayed activity, three from LS, and one from PB (table 25).  
Table 25: Active fractions from the primary biofilm formation inhibiting activity screening against S.epidermidis, 
conducted on the fractions (50 µg/mL) obtained from the LS and PB cultures. Incubation for ~24 hours. Normal 
Abs600 values for S.epidermidis when uninhibited was ~0.9. 








5.3.2.2 Secondary screening 
All fractions that were deemed active in the primary screening for biofilm formation inhibiting 
activity were retested in multiple concentrations: 50, 25, 10 and 1 µg/mL. In the secondary 
screening, none of the fractions gave Abs600 measurements beneath the cut-off value (0.25). 
Two fractions, LSC3F5 and PBC7F5, displayed some activity, with Abs600 values ~0.3 at the 
highest concentration (figure 17), and were nominated for dereplication. The fractions LSC2F6 
and LSC7F5 lost all activity, and the work on the fractions was terminated (results not shown). 
 
Figure 17: Results from the secondary biofilm formation inhibiting activity screening of the active fractions 
obtained from LS and PB cultures. Two fractions had confirmed bioactivity against biofilm formation of 
S.epidermidis: A) LSC3F5 and B) PBC7F5, after ~24 hours of incubation. The retest was conducted at 50, 25, 10 
and 1 µg/mL. 
5.3.3 Anticancer activity screening 
5.3.3.1 Primary screening 
All fractions were screened for anticancer activity against the human melanoma cancer cell line 
A2058 at 50 µg/mL, in a MTS cell proliferation assay. Twelve fractions were deemed active 
with cell survival lower than 50% (cut-off value). Five of the active fractions came from PB, 





Table 26: Active fractions from the primary anticancer activity screening (MTS cell proliferation assay) against 
A2058, conducted on the fractions (50 µg/mL) obtained from LS and PB cultures. Incubation for ~72 hours. 
Active fraction Cell survival (%) Active fraction Cell survival (%) 
LSC1F6 48 LSC7F5 14 
LSC3F5 33 PBC1F6 41 
LSC5F5 24 PBC2F6 44 
LSC6F4 37 PBC3F5 15 
LSC6F5 1 PBC3F6 4 
LSC7F4 40 PBC7F5 21 
 
5.3.3.2 Secondary screening 
The fractions that were active against A2058 in the primary screening were further tested 
against both A2058 and a normal human fibroblast cell line (MRC-5) in the following 
concentrations: 50, 25 and 10 µg/mL. The MRC-5 cell line was included as a test for general 
toxicity. From the 12 active fractions in the primary screening, six fractions were confirmed 
active against A2058 in the secondary screening, two originated from LS (figure 18), and four 
from PB (figure 19). For the fraction LSC6F5, a dose-response activity was observed against 
both A2058 and MRC-5. The same was observed for LSC7F5, though the fraction was more 
active against A2058 than MRC-5. 
 
Figure 18: Results from the secondary anticancer activity screening (MTS cell proliferation assay) of the active 
fractions obtained from LS cultures, against A2058 (malignant) and MRC-5 (non-malignant): A) LSC6F5 and B) 
LSC7F5. The retest was conducted at 50, 25, and 10 µg/mL and the incubation period was ~72 hours. MRC-5 
included as a test for toxicity. 
Generally, for the four active fractions from PB (figure 19), a dose-response activity could be 
observed against the A2058 cancer cells, while a low general activity is seen against the normal 





Figure 19: Results from the secondary anticancer activity screening (MTS cell proliferation assay) of the active 
fractions obtained from the PB cultures, against A2058 (malignant) and MRC-5 (non-malignant): A) PBC2F6, B) 
PBC7F5, C) PBC3F5 and D) PBC3F6. The retest was conducted at 50, 25 and 10 µg/mL and the incubation 
period was ~72 hours. MRC-5 included as a test for toxicity. 
Three fractions were considered “questionable” after the secondary screening, because they 
were not as active as in the primary screening, and the cell survival at 50 µg/mL concentration 
was slightly above 50%. Three fractions had lost all activity in the secondary screening, with 
cell survival above 90% for all concentrations (results not shown). The work on the 
questionable fractions and the fractions that lost activity was terminated after the secondary 
screening. Figure 20 shows the results of the three fractions that were deemed questionable in 
the screening. The fractions gave cell survival of ~60% at 50 µg/mL for A2058, and the activity 
against the MRC-5 cells was quite similar, except for fraction LSC1F6, which did not display 





Figure 20: Activity of the three fractions that were considered questionable in the secondary anticancer activity 
screening (MTS cell proliferation assay) against A2058 (malignant) and MRC-5 (non-malignant): A) LSC1F6, B) 
LSC5F5 and C) PBC1F6. The fractions were tested at 50, 25, 10 and 1 µg/mL with ~72 hours of incubation. MRC-
5 included as a test for toxicity. 
5.4 Dereplication of active fractions from bioactivity screening 
The fractions that were active in the secondary bioactivity screenings were nominated for 
dereplication using UPLC-QToF-MS. Some of the fractions were deemed active in more than 
one screening, as displayed in table 27. In the dereplication, the active fractions were compared 
to the inactive fractions eluting before and after the active one, in order to find compounds that 
were only present, or present at higher concentrations, in the active fraction. These compounds 
are candidates for the bioactivity of the fraction. All samples were run in positive ESI mode, 
unless stated otherwise. In the following sections, the results from the UPLC-QToF-MS 
analysis and the database searches obtained during the dereplication process will be presented 





Table 27: Active fractions from the secondary screenings for antibacterial activity (active against A2058), biofilm 
formation inhibiting activity and anticancer activity. The fractions that were considered active in the secondary 
screenings were nominated for dereplication.  
Active fraction Antibacterial 
activity 
Biofilm formation 



























+ indicates activity, blank indicates no activity. Blue indicates activity in one screening, green indicates activity 
in several screenings. 
5.4.1 Case 1 – One clear candidate – LSC3F5 
Fraction LSC3F5 was deemed active in the biofilm formation inhibiting activity screenings. 
From the Base Peak Intensity (BPI) chromatograms for the active (LSC3F5) and inactive 
fractions (LSC3F4 and LSC3F6), there was especially one peak that stood out in the active 
fraction (figure 21). This peak, with retention time 7.03 and a m/z of 400.2467 was investigated, 
resulting in an elemental composition calculated to be C24H33NO4. Searching the Dictionary of 




Figure 21: BPI chromatogram ESI+ (m/z 50-2000) for the comparison of fractions LSC3F4 (inactive), LSC3F5 
(active) and LSC3F6 (inactive) from LS in the dereplication process. The arrow indicates the compound with 
retention time 7.03 (m/z 400.2467) that was further investigated.  
5.4.2 Case 2 – Interfering compounds – LSC7F5 and PBC7F5 
Two fractions from the low nutrition corn flour cultures, one from each bacterium, were deemed 
active in the bioactivity screening and they were nominated for dereplication. Fraction LSC7F5 
was deemed active in the secondary screening for anticancer activity, and fraction PBC7F5 was 
deemed active in both the anticancer and the biofilm formation inhibiting activity screening. In 
both fractions, the presence of phosphocholines was observed. These compounds have been 
observed at numerous occasions at Marbio, and the elemental composition and retention time 
in this study were consistent with previous findings. Two phosphocholines were detected in 
both fraction PBC7F5 and LSC7F5 (figure 22 and figure 23). Table 28 provides more 
information about these compounds based on the information obtained from the database 




Table 28: The calculated elemental compositions for the discovered phosphocholines (in fractions LSC7F5 and 
PBC7F5) were used for database searches. For the compound with retention time 7.89 there was one 
phosphocholine hit. Several hits for phosphocholines were found for the compound with retention time 8.38, three 
were included for illustration.  
Retention time 
(minutes) 
m/z Predicted elemental 
composition 
Results from data search 
7.89 520.3393 C26H50NO7P 1-linoleoyl-sn-glycero-3-phosphocholine 
8.38 496.3392 C24H50NO7P Multiple hits for phosphocholines: 








Figure 22: BPI chromatogram ESI+ (m/z 50-2000) for the comparison of fractions PBC7F4 (inactive), PBC7F5 
(active) and PBC7F6 (inactive) from PB in the dereplication process. The arrows indicate the compounds that 
were presumed to be phosphocholines (retention times 7.89 and 8.38).  
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In fraction LSC7F5 another compound, in addition to the phosphocholines, was investigated. 
The compound eluted at 4.38 minutes, with m/z 430.1611 (indicated with a red arrow in figure 
23). The elemental composition was calculated to be C21H23N3O7. This compound can also be 
seen in the inactive fraction LSC7F4 (retention time 4.35), but at lower levels. The elemental 
composition C21H23N3O7 was used to search the Dictionary of Marine Natural Products, 
resulting in two hits: Eurypamide C and Serratiochelin A. 
 
 
Figure 23: BPI chromatogram ESI+ (m/z 50-2000) for the comparison of fractions LSC7F4 (inactive), LSC7F5 
(active) and LSC7F6 (inactive) from LS in the dereplication process. The black arrows indicate the compounds 
that were presumed to be phosphocholines, and the red arrow shows the peak of the compound with retention time 
4.38 (m/z 430.1611). 
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5.4.3 Case 3 – Complex samples – PBC3F5 and PBC3F6 
Two fractions from the same extract, PBC3F5 and PBC3F6, displayed activity in both the 
anticancer and antibacterial activity screenings. The fractions were analysed in positive ESI, 
and the chromatograms obtained can be seen in figure 24. In this case the chromatograms were 
complicated to interpret, and there were many similarities between the two active fractions, 
giving many candidates that could be responsible for the bioactivity. The arrows in figure 24 
show examples of candidates: One compound with retention time 5.73 and one at 6.32 minutes. 
The elemental compositions were calculated and used in database searches. When searching for 
the compound with the retention time 5.73 (calculated elemental composition C23H22N2O2) 
there were no hits in the Dictionary of Marine Natural Products, nor in the Dictionary of Natural 
Products. The same was observed with the compound eluted at 6.32 (calculated elemental 
composition C28H33N3), where no hits were found in the above-mentioned databases. Since the 
fractions were complex, they were also run on negative ESI mode, but the run did not provide 




Figure 24: BPI chromatogram ESI+ (m/z 50-2000) for the comparison of fractions PBC3F4 (inactive), PBC3F5 
(active) and PBC3F6 (active) from PB in the dereplication process. The arrows indicate compounds (retention 
times 5.73 and 6.32) that were further investigated. 
5.4.4 Case 4 – Related compounds – PBC2F6 
PBC2F6 was deemed active against A2058 cells in the anticancer activity screening. In this 
case, seven compounds stood out during the analysis (figure 25). It was discovered that there 
could be some type of relationship between these compounds, because the calculated elemental 
compositions were similar. In addition, the UV data for the compounds was examined and 




Figure 25: BPI chromatogram ESI+ (m/z 50-2000) for the comparison of fractions PBC2F4 (inactive), PBC2F5 
(inactive) and PBC2F6 (active) from PB in the dereplication process. The arrows indicate compounds that were 
further investigated as a group of related compounds. 
All the seven elemental compositions (table 29) were used to search the Dictionary of Marine 
Natural Products. For one of the compounds, C21H24N2, there were seven hits in the database 
(no hits for the rest of the compounds), all from a family of compounds called hapalindole-type 




Table 29: Retention time, m/z and predicted elemental composition of seven compounds detected in the active 
fraction PBC2F6. 
Retention time (minutes) m/z Predicted elemental composition  
6.08 381.2485 C27H28N2 
5.63 333.2315 C23H28N2 
5.39 365.2051 C23H28N2S 
5.13 319.2169 C22H26N2 
4.67 305.2015 C21H24N2 
6.95 426.2916 C29H35N3 
9.16 326.3775 C22H47N 
 
5.4.5 Case 5 – Interesting compounds – LSC6F5 and PBC6F5 
Both isolates, LS and PB, were grown in the intermediate nutritional medium DSGC with dead 
bacteria of the genus Leeuwenhoekiella added to the cultures after some time growing as 
monocultures. Fraction LSC6F5 was deemed active in the anticancer activity screening and the 
antibacterial activity screening, while fraction PBC6F5 was active in the antibacterial activity 
screening. During the analysis, six compounds stood out and were present in both active 
fractions (table 30). The compounds were found to have quite similar retention times, ranging 
from 8.94 minutes to 10.41 minutes, and their fragmentation patterns and elemental 
compositions appeared to be similar. Six rhamnolipids (RLs) were predicted to be present in 
the active fractions. Some of the compounds were also found in the inactive fractions, but 
generally at lower levels. These compounds are currently being worked with at Marbio, but 
from a different marine bacterial species, and several of the compounds are confirmed to be 
RLs by structure elucidation.  
Table 30: The retention time, m/z and calculated elemental compositions of the compounds suspected of being RLs 
in fractions LSC6F5 and PBC6F5. 




m/z Calculated elemental 
composition 
RL1 * 8.94 527.3190 C26H48O9 
RL2 9.71 699.3923 C34H60O13 
RL3 * 9.74 553.3349 C28H50O9 
RL4 10.08 701.4082 C34H62O13 
RL5 * 10.10 555.3505 C28H52O9 
RL6 10.41 581.3685 C30H54O9 
*This RL has been previously isolated at Marbio and it has been confirmed as a RL by structure elucidation. 
The fragmentation patterns and calculated elemental compositions from this study matches the 
previous findings at Marbio. Figure 26 shows the BPI chromatograms of active fraction 
LSC6F5 and the inactive fractions LSC6F4 and LSC6F6. The same compounds were found in 
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fraction PBC6F5 (results not shown). The elemental compositions were calculated for all the 
possible RLs (table 30). All RLs were calculated as sodium-adducts. 
 
Figure 26: BPI chromatogram ESI+ (m/z 50-2000) for the comparison of fractions LSC6F4 (inactive), LSC6F5 
(active) and LSC6F6 (inactive) from LS in the dereplication process. The same compounds were investigated in 
fraction PBC6F5. The arrows indicate the predicted RLs. The same compounds were discovered in PBC6F5 
(results not shown). 
5.5 Bioactivity as a function of cultivation conditions 
The aim of the study was to investigate whether changing the cultivation conditions for PB and 
LS could trigger the bacteria into producing different secondary metabolites, and to see how 
this affected the bioactivity. All the results from the bioactivity screenings and the dereplication 
of the active fractions have been reported in the previous sections. Here, the bioactivity results 
(the fractions that were considered active through both the primary and the secondary 
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screening) are put together with the cultivations. Table 31 and table 32 shows a compilation of 
the activity observed in fractions, coupled to what cultures these fractions originated from, for 
LS and PB, respectively. Three of the seven cultures prepared with LS gave fractions that 
displayed bioactivity. C3 gave one fraction with biofilm formation inhibiting activity, C6 gave 
one fraction that was active in both the antibacterial and anticancer activity screenings and C7 
gave one fraction displaying anticancer activity. No active fractions originated from C1, C2, 
C4 or C5 from LS. 
Table 31: Bioactivity observed for the fractions prepared from all seven cultures (C1-C7) from LS after the 
secondary bioactivity screenings. The fractions were screened for antibacterial activity, biofilm formation 
inhibiting activity and anticancer activity. 






C1 High nutrition    
C2 High nutrition, added bromide 
and iron    
C3 High nutrition, co-cultivation 
with PB  +  
C4 High nutrition, cold-treatment    
C5 Intermediate nutrition    
C6 Intermediate nutrition, added 
dead marine bacteria +  + 
C7 Low nutrition   + 
+ indicates one active fraction from the culture, blank indicates no active fractions from the culture. Blue indicates 
activity in one screening, green indicates activity in several screenings. 
From the seven cultures prepared with PB, four gave fractions that displayed bioactivity (table 
32). C2 gave one fraction with activity against the cancer cell line A2058. C3 gave two active 
fractions, and both fractions were active in both antibacterial and anticancer activity screening. 
C6 gave one active fraction that was deemed active in the antibacterial activity screening. The 
low nutrition culture C7 gave one active fraction that was active with both biofilm formation 
inhibiting activity and anticancer activity. No active fractions were discovered form C1, C4 or 




Table 32: Bioactivity observed for the fractions prepared from all seven cultures (C1-C7) from PB after the 
secondary bioactivity screenings. The fractions were screened for antibacterial activity, biofilm formation 
inhibiting activity and anticancer activity. 






C1 High nutrition    
C2 High nutrition, added bromide 
and iron   + 
C3 High nutrition, co-cultivation 
with LS ++  ++ 
C4 High nutrition, cold-treatment    
C5 Intermediate nutrition    
C6 Intermediate nutrition, added 
dead marine bacteria +   
C7 Low nutrition  + + 
+ indicates one active fraction from the culture, ++ indicates two active fractions from the culture, and blank 






The aim of the study was to utilise the OSMAC approach in an attempt to trigger two Arctic 
marine bacteria into producing secondary metabolites with interesting chemistry and 
bioactivity. The bacteria were cultivated under seven different cultivation treatments, and the 
secreted secondary metabolites were subsequently harvested and extracted from the cultures. 
Further, the extracts were prefractionated, and screened for antibacterial activity, biofilm 
formation inhibiting activity and anticancer activity. The active fractions were dereplicated by 
UPLC-QToF-MS analysis followed by database searches. The latter step was done in an attempt 
to identify the compounds responsible for the observed bioactivities.  
6.1 Cultivation, extraction and prefractionation 
Two marine bacteria (LS and PB) were chosen for cultivation. LS is classified under the class 
Actinobacteria, the bacterial class that seems to be one of the most investigated from the marine 
environment with regards to bioactive compounds (Manivasagan, Venkatesan, Sivakumar, & 
Kim, 2013). PB is a bacterium within the class Flavobacteria, which appears to be a less 
investigated class of bacteria. The bacteria were both cultivated under seven different 
cultivation treatments (figure 27). Four different media, with varying nutritional levels, were 
used for cultivation. The DVR_2 medium consists of the same components as the DVR_1 
medium, but with the addition of bromide and iron, which are important marine nutrients. These 
two media were tested to investigate how small differences in media composition could affect 
the bioactivities displayed by the cultures. Media composition can have great impact on the 
molecules that are produced. Some compounds induce production of secondary metabolites 




Figure 27: The seven different cultivations treatments of LS and PB (C1-C7). DVR_1 (C1,C3 and C4) and DVR_2 
(C2) were the high nutrition media, DSGC had intermediate nutrition and corn flour medium (C7) had low 
nutrition. As can be seen in the figure, several other cultivation parameters were altered for cultivation treatments 
C2, C3, C4 and C6.  
In addition to varying the medium used for cultivation, for some of the cultures other parameters 
were altered in an attempt to trigger the bacteria into activating different metabolic pathways 
(figure 27). C4 was cold-treated, to observe how the bacteria responded to temperature changes, 
with the temperature being decreased to almost freezing point several times. C3 and C6 were 
supplemented with additional bacteria, in an effort to trigger the bacteria into producing 
compounds of antibacterial nature to out-compete the intruder (supplemented bacteria). In the 
C3 cultures, PB was added to LS and vise versa. Before extracting the cultures, they were plated 
to check if both bacteria had survived the cultivation. In both cases, the supplemented bacteria 
could not be detected on the plates, indicating that the primary bacteria had outgrown them. In 
C6, dead bacteria (Leeuwenhoekiella sp.) was added to the cultures after some time as 
monocultures to see how the bacteria responded to the addition of dead bacteria. It should be 
made clear that the supplemented bacteria in C3 and C6 was not of the same species, and studies 
have shown that the species chosen for co-cultivation has great influence of the compounds that 
are produced (Trischman et al., 2004). The topic of co-cultivation will be further discussed in 
section 6.4 “Bioactivity as a function of cultivation conditions”. There will always be several 
other parameters that can be tested when cultivating bacteria with the goal of activating different 
metabolic pathways. The choice of cultivation treatments in this thesis (C1-C7) display quite a 
broad spectrum of conditions, with alterations in media, temperature and by addition of bacteria.  
The weight of the extracts from the LS cultures, especially for the high nutrition cultures, were 
higher compared to the PB cultures. For C5-C7 the weight of the extracts was quite similar 
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between the two bacteria. Based on the weight of the media control (MC) extracts (figure 12), 
it is apparent that the resin used is efficient in extracting media components, especially for the 
high nutrition media DVR_1 and DVR_2. Because of this, one can not be certain that high 
extract weights reflects high production of secreted metabolites, or that simply the media 
components are also being extracted. Therefore, LS is not necessarily a better producer of 
secreted secondary metabolites or biomass. It might be that PB is producing more secondary 
metabolites, which generally are low molecular weight compounds, which are better adsorbed 
by the resin, while the LS extracts contain higher amounts of media components. In order to 
say anything certain about what strain is the better producer, or what conditions gave the best 
production of secondary metabolites, one would have to measure the growth of the bacteria 
(biomass production) and the secretion of metabolites for each culture.  
The extracts were prefractionated, giving six fractions (F1-F6) from each extract. Only fractions 
F4-F6 were deemed active in the bioactivity screenings, inconveniently, these were also the 
fractions with the lowest weights. Because of the low weight of fractions, it is probable that the 
active compound is present in too low concentrations to attempt an isolation, and that new 
cultures would have to be started and processed to get enough material for isolation. When 
starting new cultures one can not be certain that the compound of interest will be produced, so 
it is important that the parameters used for cultivation are as similar as possible to the original 
culture. Since fractions F1-F3 were the ones with the highest weights, it could be that they were 
too complex, so that the activity of possibly active compounds was masked in the bioactivity 
screenings. Thus, one option would be to produce more fractions from these in an attempt to 
unmask some of the possible bioactive molecules. It has been observed at Marbio that the most 
hydrophilic fractions rarely display bioactivity, and the same was observed in this project. One 
reason for this could be that there are large amounts of water-soluble compounds that are too 
polar to penetrate the cell membranes and reach intracellular targets. Because of this, it is not 
recommended to fractionate the most hydrophilic fraction (F1) any further. 
6.2 Bioactivity screening of fractions 
The antibacterial properties of the fractions were analysed against five human pathogenic 
bacterial strains, and their ability to inhibit biofilm formation of S.epidermidis was also studied. 
In addition, the fractions were screened for anticancer properties against the cancer cell line 
A2058. To determine whether a fraction was active or not, cut-off values were used. This 
filtering is necessary at Marbio, as a high-throughput screening platform, to quickly select what 
samples to focus on, and which to terminate. The cut-off values were used as a guidance in this 
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thesis, to limit the number of fractions to prioritize for further work. Figure 28 shows the 
number of fractions at each step. The number of fractions terminated after the primary screening 
was high, with only 14 out of 84 fractions being active in the primary screening. 
 
Figure 28: Number of fractions in the workflow from the start, after the primary bioactivity screening and after 
secondary bioactivity screening.  
The results from the bioactivity screenings were not always reproducible, as some of the 
fractions that were active in the primary screenings did not display activity (or displayed less 
activity) in the secondary screenings (figure 29). This was particularly observed for the biofilm 
formation inhibiting activity screening and the anticancer activity screening, where 50% of the 
fractions no longer displayed activity in the secondary screening. These screenings were 
performed multiple times in an attempt to obtain reproducible results, but the results were non-
consistent. The antibacterial activity screening was the first bioactivity screening to be 
performed, and it was performed without having to freeze/thaw the fractions in-between the 
screenings. Here, there was a clear correspondence between the results in the primary and the 
secondary screening (see figure 29). Generally in the bioactivity screening, the most stabile 
results were obtained when using fresh plates of fractions in MQ and DMSO, and conducting 
the primary and secondary screenings without having to freeze and thaw the plates in-between 
screenings. When the fractions were dissolved in MQ with 2.5% DMSO, and stored for some 
time (less than one week), the precipitation of dark pigmented compounds was observed in the 
test-DWPs. It is highly likely that this precipitation had an effect on the activity of the fractions. 
Cycles of freezing and thawing can have effects on the degradation and precipitation of 
compounds (Kozikowski et al., 2003). One possibility would be to prepare new plates for each 
screening. In this way, the fractions could be dissolved in MQ/DMSO on the day of the screen, 
and the fractions would be completely “fresh” for the screening. The downside of this is that 
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preparation of plates takes time, having to add each sample individually, freezing, freeze drying 
and then dissolving the fractions.  
 
Figure 29: Number of fractions deemed active in the primary and secondary bioactivity screenings. All fractions 
were screened for anticancer, biofilm formation inhibiting and antibacterial activity. 
None of the fractions displayed activity against the Gram-negative test strains in the 
antibacterial activity screening. This is consistent with observations at Marbio, where there are 
generally discovered more activity against the Gram-positive bacterial strains, compared to the 
Gram-negative ones. There is a massive problem with resistance observed for many Gram-
negative bacteria, and the need for new antibiotics against these organisms is growing. One 
reason why Gram-negative bacterial infections are difficult to treat is the presence of porins and 
efflux pumps in their outer membrane, which can limit the influx and increase the outflux of 
antibiotics used during infection (Neelam & Harsimran, 2016). Because of this, it is important 
to find new antibiotics that can tackle the resistance of Gram-negatives. One approach could be 
to co-cultivate the marine bacteria with Gram-negative bacteria, to see if this could trigger the 
production of compounds that are selectively active. There are however also several human 
pathogens that are Gram-positive, and many of these bacteria, among them S.aureus and 
S.pneumoniae, are causing global resistance challenges (Woodford & Livermore, 2009), so the 
need for new antibiotics against Gram-positive bacteria is also urgent. Of the 12 
pathogens/groups of pathogens listed in the WHO priority pathogen list (table 2) nine are 
classified as Gram-negative and three are Gram-positive (WHO, 2017b). With the global threat 
of antibiotic resistance, and seeing that the possibility of treating infections is essential in many 
aspects of health care (e.g. surgeries), it is becoming especially important to focus the research 
towards finding new antibiotics.  
Six fractions were confirmed active against the A2058 cancer cell line. The fractions deemed 
active in the primary screening were also screened against the non-malignant lung fibroblast 
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cell line MRC-5 as a test for general toxicity. Generally, it seemed that the fractions displayed 
some activity against the MRC-5 cells, but more activity against the cancer cells. Many of the 
cancer drugs on the market today are cytotoxic compounds, also affecting the normal cells in 
the body (Ambili, 2012). The goal is to have a drug with greater effect against the cancer cells 
than the normal cells, so the treatment is effective enough without destroying the normal cells 
in the body. Activity as seen for fraction PBC3F6 (figure 19) is preferable: The activity of the 
fraction is considerably higher against the cancer cells than the normal cells, and a dose-
response activity is observed (the activity decreases with decreasing concentration). Even if the 
compound of interest display some activity against normal cells, it is common to optimise 
compounds to give properties more suitable for its target (e.g. cancer cells). This process is 
called lead optimisation, where analogues of the active compound is produced and screened 
with the goal of producing a well-suited drug (Flannery, Chatterjee, & Winzeler, 2013).  
As can be seen in the results (table 27), many of the active fractions were active in more than 
one bioactivity screening. Of the eight fractions that were considered active in the secondary 
screenings, four fractions were active in two bioactivity screenings and four were active in only 
one bioactivity screening. Activity in multiple bioactivity screenings can be considered a 
negative feature, since it might be a sign of non-specific inhibition. It could be that the active 
compound is destroying the cell membrane, and is in this way able to affect different types of 
cells. Another possibility is that it is not the same compound that is producing the activity in 
the different bioactivity screenings. Using biochemical (cell-free) assays in addition to cell-
based assays (as used in this study) is a good way to further characterise whether or not the 
activity is specific, and to learn more about the actual activity of the different compounds. 
Biochemical assays are in vitro based methods that measures the activity of 
fractions/compounds towards a specific biological molecule, for example an enzyme (Arkin et 
al., 2017, p. 102). 
6.3 Dereplication of active fractions from bioactivity screening 
The final task of the project was to conduct the dereplication analysis, aiming at identifying the 
compound(s) within the active fractions responsible for the observed bioactivity. Isolation and 
structure elucidation can be very time and resource consuming, which is why effective and 
thorough dereplication is an important part of NP drug discovery. There is however no 
guarantee that the isolated compound is responsible for the observed biological activity detected 
in the screening (Wagenaar, 2008). The information you get from the dereplication process is 
used to decide whether the work on the sample is terminated, or that the compound of interest 
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is isolated and worked with further. In this study, eight active fractions were analysed on the 
MS and compared to the inactive fraction eluted before, and the inactive fraction eluted after in 
the prefractionation process.  
As highlighted in the introduction, PAINS are molecules with broad and non-specific activity 
that might mask the activity of interesting compounds, leaving the interesting compounds un-
detected. Two of the active fractions contained phosphocholines (LSC7F5 and PBC7F5), 
compounds that have been encountered several times at Marbio, and are considered PAINS 
(Hansen & Andersen, 2016). Because of their non-specific activity, and the fact that 
phosphocholines have been thoroughly investigated, these compounds are not considered 
relevant for drug discovery and the work on such fractions is normally terminated.  
For fraction LSC7F5 (displaying anticancer activity) another compound, in addition to the 
phosphocholines, was investigated. The compound gave the highest peak in the chromatogram, 
and it was present in higher concentration in the active fraction compared to the inactive 
fractions. Searching the Dictionary of Marine Natural Products gave two hits: Eurypamide C 
and Serratiochelin A. The eurypamides are cyclic isodityrosines, like the antibiotic 
vancomycin. Cyclic isodityrosines have been reported with several bioactivities. Eurypamide 
C was originally isolated from a marine sponge, and has no reported bioactivity (to my 
knowledge) (Ito, Yamanaka, Kutsumura, & Nishiyama, 2003; Rami Reddy, Harper, & 
Faulkner, 1998). It would be interesting to isolate the compound for several reasons: Even 
though the compound has been isolated from a sponge, as previously mentioned, the actual 
producers of many isolated bioactive molecules (isolated from macroorganisms) are often 
associated bacteria. Therefore, isolation would say something about the origin of the compound, 
and even though it is a known compound, it might have a newly discovered bioactivity 
(anticancer). Serratiochelins are siderophores, compounds produced by bacteria that are 
responsible for acquiring iron from the environment (Seyedsayamdost et al., 2012). Since the 
compound has been mostly investigated for its iron-acquiring properties, it does not seem like 
it has been thoroughly investigated for other bioactivities. Serratiochelin A have no reported 
anticancer activity (to my knowledge). Further investigation would be interesting for both 
possibilities (Eurypamide C and Serratiochelin A), but the fact that none of the compounds have 
reported bioactivities makes it even more probable that the phosphocholines (with several 
reported non-specific bioactivities) were responsible for the observed activity of the fraction. 
Fraction LSC3F5, active in the biofilm formation inhibiting activity screening, had one peak 
that clearly differed from the active fraction and the inactive fractions. The calculated elemental 
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composition was C24H33NO4, which gave two hits in the Dictionary of Marine Natural Products: 
Aspochalasin C and Phomasetin. To my knowledge, none of these molecules have been isolated 
from bacteria before, and in the literature the compounds are referred to as fungal metabolites. 
The Aspohalisins, also called cytochalasins, have displayed different interesting bioactivities, 
among them antibacterial activity (Betina, Micekova, & Nemec, 1972; Gebhardt et al., 2004). 
With the possibility of discovering new bioactivities (inhibition of biofilm formation), this 
compound would be interesting for isolation and further investigation. Phomasetin is also a 
fungal metabolite, found moderately active against immunodeficiency virus integrase (Singh et 
al., 1998). If this is the actual compound responsible for the observed activity, it would be 
displaying a novel bioactivity as well. In order to say more about this compound, it would have 
to be isolated, have its structure elucidated, and be retested for bioactivity as a pure compound.  
Two fractions from the same extract, PBC3F5 and PBC3F6, were deemed active in both the 
anticancer and the antibacterial activity screenings. Since the fractions displayed similar 
activity, and were adjacent fractions from the prefractionation, it is highly probable that the 
active compound(s) were the same in both fractions. The chromatograms were difficult to 
interpret with many similar peaks in both fractions, but two candidates were suggested for the 
observed bioactivities: C23H22N2O2 and C28H33N3. Searches using the Dictionary of Marine 
Natural Products, and the Dictionary of Natural Products gave no hits. The compounds are good 
candidates for the observed bioactivity, and continuous work with isolation, structure 
elucidation and further bioactivity screening is recommended for the possibility of finding novel 
bioactive compounds.  
Fraction PBC2F6 was deemed active against the A2058 cancer cells. Here, a group of seven 
compounds were detected in the fraction and investigated. The compounds were similar with 
regards to elemental compositions and UV data, which led to the hypothesis that this might be 
a group of compounds with some type of relation, e.g. as degradation products or as biosynthetic 
intermediates. One of the seven compounds gave hits in the Dictionary of Marine Natural 
Products (no hits for the other six compounds). All hits were hapalindole-type NPs, previously 
isolated from different cyanobacteria (Kim et al., 2012; Richter et al., 2008). The hapalindole-
type NPs have displayed a wide range of bioactivities, among them anticancer activity (Richter 
et al., 2008). Being that the compounds previously have been isolated from cyanobacteria, it 
could either be that the compounds of interest are not from this group of compounds, or that the 
compounds are in fact (also) produced by other bacteria (non-cyanobacteria). Since the 
compounds have displayed a wide range of bioactivities, it would be interesting to see if some 
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of the compounds in this fraction are new variants of these NPs. The next steps would be to 
isolate the compounds, get their structures determined and then screening for different 
bioactivities (bioactivity profiling).  
In case five of the dereplication, fractions LSC6F5 and PBC6F5 were predicted to contain 
different rhamnolipids (RLs) (see table 30). LSC6F5 was deemed active in the anticancer 
activity screening and in the antibacterial activity screening, while PBC6F5 displayed 
antibacterial activity. These metabolites are produced by different bacteria, with P.aeruginosa 
being the most commonly found producer (Chrzanowski, Ławniczak, & Czaczyk, 2012). RLs 
have been reported to display several different bioactivities, among them antimicrobial 
properties (Abdel-Mawgoud, Lépine, & Déziel, 2010). RL1, RL3 and RL5 have previously 
been isolated at Marbio, from a different marine bacterium, and their structures were confirmed 
by structure elucidation (nuclear magnetic resonance spectroscopy). RL2, RL4 and RL6 would 
have to be isolated for an absolute confirmation, but the fragmentation pattern and elemental 
compositions strongly indicates that these are in fact RLs. Literature searches strengthened this 
hypothesis (figure 30). In a mini-review by Abdel-Mawgoud and co-workers the structures and 
elemental compositions of known RLs are listed (Abdel-Mawgoud et al., 2010), and all six 
predicted elemental compositions from this thesis (table 30) are present in this list.  
 
Figure 30: Chemical structure of different identified rhamnolipid congeners. Modified from reference (Abdel-
Mawgoud et al., 2010, p. 1325). Rhamnolipids are glycolipids, made up of one or more rhamnose parts and one 
or more lipidic parts. From the elemental compositions calculated for the RLs predicted in this study, they appear 
to be Mono-Rhamno-Di-Lipidic (RL1, RL3, RL5 and RL6) and Di-Rhamno-Di-Lipidic (RL2 and RL4). R1, R2, n1 
and n2 are variables that differs in the RLs that have been identified. 
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The RLs were detected in fractions from both PB and LS, but from the same cultivation 
treatment (C6) where dead Leeuwenhoekiella was added. This gave reason to believe that the 
RLs originated from the Leeuwenhoekiella sp. culture. One of the drawbacks with cultivating 
several bacteria together is that one can not be certain of which bacterium is the true producer 
of the active compound(s). The culture with dead Leeuwenhoekiella was plated before 
inoculation with LS and PB, and no growth was observed on the plates, strongly indicating that 
the bacteria were dead before addition to the cultures. If this bacterium was the producer of the 
RLs, they must have been produced before the addition to the PB and LS cultures. A control 
prepared with dead Leeuwenhoekiella was analysed on the MS to search for the RLs. In the 
control, the three previously detected RLs were re-discovered (RL1, RL3 and RL5), indicating 
that the RLs were in fact produced by the Leeuwenhoekiella bacterium. In cultivation C5, both 
LS and PB were cultivated in DSGC, but without the addition of the dead bacteria. Fractions 
from these two cultures were also analysed to see if the RLs could have been produced by the 
monocultures. In the LSC5 fractions RL3 and RL5 were detected. No RLs were discovered in 
the PBC5 fractions. Based on all this data, it is suggested that both LS and Leeuwenhoekiella 
produced RLs under these cultivation treatments, while it did not seem that PB were able to 
produce RLs. To my knowledge, neither LS or Leeuwenhoekiella have been reported as RL 
producers previously. Since RL2, RL4 and RL6 were not detected in the Leeuwenhoekiella 
culture, it is possible that LS and PB were capable of modifying these from RL1, RL3 and RL5 
when co-cultivated. Further work on the RLs will be conducted at Marbio. 
6.4 Bioactivity as a function of cultivation conditions  
From the bioactivity screenings conducted in this study, it was clear that some of the 
cultivations were more successful in producing bioactive fractions (containing bioactive 
compounds) compared to others (figure 31). Between the two strains it seemed to be quite even, 
with three active fractions from LS and five from PB after the secondary screenings. For both 
strains, activity was observed in fractions from cultivations C3, C6 and C7, and for PB there 
was also one active fraction from C2. It seems that the supplementation of a different bacteria 
had an impact on the production of bioactive molecules from the marine bacteria, since both 
bacteria produced active fractions from these cultures (C3 and C6). These two cultivations 
contributed with 63% of the fractions considered active after the secondary screenings (see 
figure 31). It should be emphasised, as previously mentioned, that one can not be certain of 
what organism is the true producer of the active compound(s) in a co-cultivation, as was 
observed with the RLs that were encountered in this study. There are several studies on co-
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cultivation as a means of triggering the expression of otherwise silenced genes. It is performed 
as an attempt to mimic the natural ecological situation for the microorganisms, where they 
persist in complex microbial communities. Co-cultivation has led to production of compounds 
that were not detected in the corresponding monocultures. This was observed when co-
cultivating different bacterial strains, all isolated from the same algae, Ulva california 
(Trischman et al., 2004). In the antibacterial activity screening, all active fractions originated 
from C3 and C6, and one of two fractions deemed active in the biofilm formation inhibiting 
activity screening originated from C3, which is an indication that the supplementation of 
bacteria to the cultures influenced the activity against bacterial growth and biofilm formation. 
The results from this thesis indicates that co-cultivation and addition of dead bacteria triggers 
LS and PB to activate different metabolic pathways, compared to the corresponding 
monocultures. 
 
Figure 31: Cultivations providing fractions confirmed active in the secondary bioactivity screenings. Eight 
fractions were confirmed active. C1, C4 and C5 did not provide any confirmed active fractions. 
From the low nutrition cultures (C7) both bacteria produced active fractions. This indicates that 
stressing the bacteria with low nutrition can induce the production of different bioactive 
metabolites. Another explanation is that specific components in the corn flour medium (low 
nutrition) triggered the bacteria to alter their metabolic pathways. Lastly, PBC2 provided one 
fraction with confirmed anticancer activity. C2 were the cultures where bromide and iron were 
added to the culture medium, indicating that this addition triggered PB to altering its synthesis 
of metabolic products. Further work could be to test the addition of other common marine 
nutrients (e.g. chloride and potassium) to investigate how this affects the cultures of Arctic 
marine bacteria. Fractions from the cultures C1, C4 and C5 did not display activity reaching the 
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cut-off values used in this thesis. C1 and C5 were cultures grown in high and intermediate 
nutrition medium, respectively, where no additional parameters were altered. It also appeared 
that stressing the bacteria with low temperatures (C4) did not induce the production of bioactive 
molecules, at least none that were detected in the bioactivity screenings in this project. There is 
always the possibility that there could be compounds with bioactivities that are not being 
screened for.  
The main findings in the work of this thesis was that small alterations in cultivation parameters 
can have a considerable influence on the bioactivity displayed from the cultures. From the 
results, it is obvious that the biosynthetic production of the bacteria is highly dynamic and 
influenced by the cultivation conditions. The most successful cultivations, in terms of providing 
bioactive fractions, were those where additional bacteria was supplemented, the low nutrition 
cultures and the PB culture where bromide and iron was added to the medium. In this study, 
only two bacteria were cultivated and seven different cultivation treatments were conducted on 
the bacteria. The parameters that can be altered are endless, which makes the potential of NP 




7 Conclusions and further work 
Two Arctic marine bacteria were successfully cultivated under seven different cultivation 
treatments, utilising the OSMAC approach. Extracts were prepared and prefractionated, and the 
fractions were screened for different bioactivities. There were several active fractions, with 
antibacterial activity, biofilm formation inhibiting activity and anticancer activity. The 
dereplication of the active fractions gave possible candidates responsible for the observed 
activity. For further work on compounds of interest, new bacterial cultures have to be started 
and processed to isolate these compounds in sufficient amounts for structure elucidation and 
bioactivity screening.  
The thesis has demonstrated that LS and PB are capable of producing different bioactive 
compounds. It also showed that the cultivation conditions affected the compounds produced by 
the bacteria, and the bioactivity of the fractions produced from the cultures. With these regards, 
utilising the OSMAC approach was successful in this project. The possibilities with the 
OSMAC approach are endless. Testing different cultivation parameters and gaining more 
knowledge on what physiological conditions activate genes in charge of secondary metabolism 
would make the approach even more efficient, and will provide interesting bioactive 
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Table 33: The products used for preparation of the M19 medium used in the Leeuwenhoekiella culture. 
Product   Product ID Distributor (Country) 
Filtered sea water  Norwegian College of Fishery 
Science (Norway) 
D-Mannitol 63560 Sigma-Aldrich (Missouri, USA) 
Peptone from casein, enzymatic 
digest 
82303 Sigma-Aldrich (Missouri, USA) 
 
For the cultivations C6, both strains (LS and PB) were cultivated in DSGC medium and dead 
bacteria of the Leeuwenhoekiella sp. was added. Leeuwenhoekiella was grown in M19 medium, 
which contained the following: 
 Filtered sea water    50% 
 MQ      50% 
 D-Mannitol     20 g/L 
 Peptone from casein, enzymatic digest 20 g/L 






Table 34: The products used for preparation of PBS and trypsin solution used for maintenance of the cells in the 
anticancer activity screening. 
Product Product ID Distributor (Country) 
Potassium chloride 1.04935 Merck KGaA (Germany) 
Potassium dihydrogen 
phosphate 
1.04871 Merck KGaA (Germany) 
Sodium Chloride S5886 Sigma-Aldrich (Missouri, USA) 
Sodium phosphate dibasic 
dihydrate 
30412 Sigma-Aldrich (Missouri, USA) 
Trypsin (1:250) 27250018 Thermo Fisher Scientific 
(Massachusetts, USA) 
Ethylenediaminetetraacetic acid 
disodium salt dehydrate (EDTA) 
E1644 Sigma-Aldrich (Missouri, USA) 
 
Phosphate Buffered Saline (PBS) was used to wash the cells of cell medium before trypsinating. 
The PBS was prepared with the following ingredients: 
 Potassium chloride    0.2 g/L 
 Potassium dihydrogen phosphate  0.2 g/L 
 Sodium chloride    8 g/L 
 Sodium phosphate dibasic dihydrate  2.16 g/L 
The buffer was prepared with MQ and autoclaved before use at 121°C for 120 minutes. 
The trypsin solution used to loosen the cells from the culture flasks was prepared with the 
following ingredients: 
 Trypsin 25 g/L 
 EDTA  5 g/L 
PBS was added up to one liter, and the solution was sterile filtered (0.2 µm filter) and 50 mL 
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